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ABSTRACT 
The effect o! !ormulation !actors on the efficacy of 
the antiperspirant agent, aluminum chlorhyd.rate, was 
studied. The formulation variables include the various 
carrier vehicles for the topically applied active ingredient. 
Qunatification of antiperspirant efficiency was evaluated by 
a generally accepted gravimetric technique by application o! 
a known amount of active ingredient to the axillae o! human 
volunteers. 
Aluminum chlorhydrate was solubilized in a cream 
base, an aqueous lotion, and a hydroalcholic base, and 
was suspended in a solid stick. Aluminum chlorhydroxy 
allantoinate was incorporated into all vehicles for its 
therapeutic and cosmetic properties. All test antiperspir-
ant products were selected on the basi_s of cosmetic elegance 
and acceptability. 
The four vehicles containing aluminum chlorhydrate 
were compared for efficacy by a well-recognized gravimetric 
procedure during a normal work day in each subject's normal 
work environment. A pretest sweat collection was used as a 
blocking factor in designing the 4 by 4, split plot, Latin 
Square. Post-test sweat collection data were evaluated 
ii 
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statistically using the geometric mean of treatment results. 
All ratio treatment means were converted to percent sweat 
reduction to determine antiperspirant efficiency. 
The carrier vehicle does not af'f ect antiperspirant 
efficacy. However, efficacy differences were observed as 
a function of solution versus suspension. Treatment 
response in terms of percent sweat reduction was: aqueous 
lotion, 38.0'~; hydroalcoholic solution, 32.4%; cream base, 
31.8%, and solid stick, '-6.:2%. Statistical analysis 
indicated that the side treated may be selected randomly 
without compromising the results. Sweat weights may be 
af'fected by temperature, muscular exercise, or emotional 
stress without affecting antiperspirant effectiveness. 
iii 
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I. OBJECTIVES 
Many drugs and cosmetics are applied topically, 
resulting in various kinds of dermal activity. These items 
include various types and classes of emollients, anti-
infectives, sunscreens, keratolytics, antibacterials, and 
antiperspirants. The activity of topically applied drugs 
depends on such factors as solubility, particle size, 
acid-base function, percutaneous absorption, and stability. 
In some instances, drug efficiency has been shown to be 
dependent on the carrier vehicle in which the drug is 
placed (1-10). 
The literature is replete with reports of the 
efficacy of dermally applied antiperspirant agents (10-20); 
however, there is a paucity of published information on the 
effect of vehicle on antiperspirant efficacy. This gap in 
such data became pronounced very recently for two reasons: 
the Food and Drug Administration's Over-The-Counter Drug 
Review Panel's review of antiperspirants for "• •• safety, 
toxicity, and efficacy of the product and its component 
ingredients" (21); and the Federal Register May 1977 
decision to · phase out fluorocarbon-propelled aerosols (22). 
The present study is concerned with: 
1. The effect of vehicle on antiperspirant efficacy. 
2. The influence of the active ingredient's state, 
1 
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(e.g., suspension versus solution) on antiperspirant 
e!!icacy. 
3. Quantification o! antiperspirant efficiency using 
a gravimetric technique (23-27) under normal conditions o! 
use. 
4. Developing a statistically sound experimental 
design, which eliminates side treated differences, to 
evaluate antiperspirant efficacy data. 
II. INTRODUCTION 
A. Anatomy and Physiology of the Sweat Glands 
The axilla is the cavity beneath the shoulder joint, 
commonly referred to as the armpit. It is a unique skin site 
in that it i~ a moist, intertriginous area containing both 
sebaceous glands and sudoriferous or sweat glands. The 
latter are present in the stratum corneum or surface horny 
layer, a keratinous layer of flat, denucleated, dead cells, 
approximately 600 um thick in the horny pads of the palms 
and soles and 15 um thick in the membranous horny layers 
such as the axillae (2S'). 
Perspiration has a physiologically important role. 
Insensible perspiration is the loss of water in the form 
of vapor from the body into the air through the skin and 
respiratory passages. Sensible perspiration, known as 
sweat, is the visible delivery of sweat droplets from the 
sweat glands to the skin surface. The principal functions 
of perspiration are the maintenance and control of body 
temperature and waste excretion, but it also contributes 
to the hydration and plasticization of the stratum 
corneum (29,;o). 
There are two distinct functional and anatomical 
structures responsible for the production of sensible 
perspiration: the apocrine and eccrine sweat glands. 
( 
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The eccrine sweat glands are distributed throughout the 
skin surface, with the exception of the lips and genital 
organs. Most are in the palms and soles. They are tubular 
structures consisting of a secretory coil in the lower dermis 
with a duct leading directly to the skin surface (Figure 1). 
The eccrine sweat glands are well-developed and functional 
from birth throughout an individual's life span (32). They 
aid in the regulation of body temperature and maintenance of 
skin elasticity (33). 
The apocrine glands are distributed among the axillae, 
breasts, and urogenital areas. They are structurally similar, 
to the eccrine glands, but they are larger in size and fewer 
in number. The apocrine glands consist of a coiled secretory 
tubule in the dermis, leading upward to the duct attached to 
a hair follicle. At least one apocrine gland is attached 
to each hair follicle in the axillae (34). In children, 
small, undifferentiated apocrine glands lie deep in the 
dermis. From the seventh year to adolescence the glands 
become progressively larger and well-differentiated, but 
not functional. 'lbey develop at puberty and remain 
functional for life, although they decrease in size and 
activity after menopause (35). Extensive studies of 
apocrine gland activity have attempted to correlate 
structural and functional variations of the apocrine gland 
with hormonal changes without success (36,37). Researchers 
regard apocrine sweating as a secondary sexual character-
istic, associated with sexual attraction among peoples 
ECCRINE 
GLAND 
\ 
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APOCRINE 
GLAND 
~ 
Figure 1. Diagram of eccrine and apocrine 
glands in relationship to other cutaneous 
appendages (31). 
6 
throughout the evolution of the human species (29,38~0). 
B. The Physiology of Sweat Secretion 
Sweat secretion is controlled by the sympathetic 
nervous system. The temperature-regulating center in the 
hypothalamus controls thermal sweating, while emotional 
sweating, most likely to occur in the palms, soles, and 
axillae, is controlled by a cortical center. 
Eccrine sweating is a continuous process that is 
innervated cholinergically by acetylcholine and 
adrenergically by epinephrine. Ibe nerve fibers 
surrounding the eccrine sweat glands respond to emotional 
as well as thermal stimuli. 
The actions of acetylcholine are either muscarinic 
or nicotinic. Pilocarpine and adrenalin produce a direct 
muscarinic response of local eccrine sweating; while 
indirect, widespread, nicotinic response will follow 
intradermal injections of acetylcholine, metacholine, 
and carbachol (41). 
Anticholinergics (e.g., atropine) and gan~lionic 
blockers (e.g., hexamethonium) inhibit eccrine sweating. 
Atropine has been used clinically to treat hyperhidrosis. 
However, the severe parasympathetic side effects and tO:xiicity 
associated -with atropine's frequent use and its tendency 
to hydrolyse rapidly has limited its usefulness to 
experimentation only (42-44). Various anticholinergic salts 
and esters have exhibited greater stability. In one study 
( 
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topical application of 1% scopolamine hydrobrom.ide for five 
consecutive days effectively inhibited sweat for one 
month (45). Recent studies showed glycopyrrolates produced 
topical suppression of eccrine sweat. Their use was 
accompanied by a marked decrease in local or systemic adverse 
effects (46) • . 
Apocrine sweating, adrenergically innervated by 
epinephrine and emotional stimuli, is an intermittent 
process with a refractory period from 24 to 48 hours (33,47). 
The physical stimulus of compressing the axillary skin in a 
gentle, sliding motion, as in the case of the axilla being 
rubbed by a swinging arm during walking, causes the 
appearance of apocrine sweat (~7). 
Direct pharmacological stimulation of the apocrine 
glands results from intradermal injections of epinephrine, 
norepinephrine, and neosynephrine. Pilocarpine increases 
the metabolic rate of apocrine glands. New evidence suggests 
that apocrine sweating may be induced by the contractions 
of the muscles surrounding the apocrine sweat tubules and not 
solely by adrenergic stimulation (37,44). 
Dibenamine selectively inhibits apocrine sweating, 
but it is too toxic for clinical use. The imidazolines, 
Regitine and Priscoline, are safe and effective in reducing 
apocrine sweating (44). 
( 
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c. Perspiration Composition 
Perspiration, a mixture of organic and inorganic 
matter in a ratio of approximately 1:3, is sterile and 
odorless. Eccrine glands secrete a clear, colorless, 
watery fluid that is 99% water. The remainder is a mixture 
of inorganic ions such as sodium, chloride, potassium, 
calcium, iron, manganese, magnesium, and copper together 
with certain .organic compounds such as lactic, citric, and 
ascorbic acids, urea, and nitrogenous compounds (38,48,49). 
Eccrine sweat has a pH of 4.0-7.0, the higher pH range 
usually from axillary perspiration. Intertriginous 
surfaces, such as the axillae, inhibit sweat evaporation 
causing a neutralization and dilution of free acids which 
promote hydrolysis of nitrogenous material and result in a 
pH increase in sweat on the skin surf ~ce (47). 
The apocrine glands secrete an opalescent, 
turbid-white fluid that emerges from the hair follicles and 
spreads over the skin surface, which, if not diluted by 
eccrine sweat, dries rapidly to form a glistening film. 
(47,50). This fluid contains water, sodium chloride, 
proteins, lipids, and a high ammonia content which results 
in a pH of 6.0-7.5 (49,51). Generally, the pH of apocrine 
sweat is 0.5 pH units higher than eccrine sweat in a given 
individual. ~his is attributed to the high ammonia 
concentration in apocrine sweat (52). 
( 
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D. Disorders of the Sweat Glands 
There are cases of functional disorders o! the sweat 
glands. Hyperhidrosis or excessive perspiration is one of 
the major disorders. General hyperhidrosis is usually a 
result of excessive heat, exertion, or certain drugs as 
acetylcholine, or adrenalin. Local hyperhidrosis usually 
affects the axillae or palms or soles. It originates in the 
apocrine glands as a result of stapbylocci infections or from 
an initial dermatitis from deodorant/antiperspirant products 
(53). Anhidrosis, a rarely occuring disorder, is the 
diminution or even cessation of sweat. Bromidrosis, 
perspiration with an offensive smell, is usually associated 
with the apocrine glands and is a direct result of bacterial 
decomposition. Chromidrosis, abnormally colored perspiration, 
also is attributed to bacterial activity. Certain toxic and 
disease states produce hemahidrosis, which is bloody 
perspiration, or urehidrosis, which is perspiration con-
taining urine substances (54). 
E. Perspiration Malodor 
Although perspiration secreted by the sweat glands is 
sterile and free of odor, the axillae provide an excellent 
odor-producing surface. There are sufficient nutrients from 
apocrine secretions plus a warm, moist, neutral pH 
medium in which skin bacteria seem to thrive. Apocrine 
secretions that reach the skin surface are subject to 
attack by microorganisms, especially gram-positive 
staphylocci and diphtheroids, resulting in bacterial 
( 
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decomposition and the characteristic body odor referred to 
as caprylic. Axillary hair and heavy clothing, ideal 
collection sites for bacteria, increase perspiration malodor. 
Contaminated eccrine secretions, which produce a vague, 
indistinct odor unlike apocrine-generated odor, are not 
considered the main cause of offensive body odor (36,38,54, 
55). 
F. Factors Influencing Perspiration Output 
1. Racial differences. Perspiration is characteristic 
of race, family, and individual. No significant differences 
in sweat volume or sweat distribution have been found in the 
eccrine sweating patterns in Negro and Caucausian subjects, 
however, apocrine glands of Hegroes are larger, more 
numerous, and have shorter refractory periods than Caucausians. 
Moreover, chromidrosis occurs more frequently in Negroes. 
Mongolian races have relatively inactive apocrine glands. 
In any event, females have more, but smaller apocrine glands 
than males regardless of race. Humans produce an average of 
one to three pints of eccrine sweat in 24 hours, regardless 
of race, sex, ·-or .individual. Eccrine sweat accounts for the 
major portion. o! total volume of axillary perspiration with 
only small volumes of apocrine and sebaceous secretions (50). 
2. Therm.al and emotional stimuli. Quantitative 
studies of varying thermal and emotional stimuli have noted 
differences in perspiration volume (11,24,56-58). High 
( 
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temperatures of 80-100°F and high humidities with little air 
movement cause an overproduction -of axillary sweat because 
cooling is impaired. 
YJ.ental stimuli ranging from mental arithmetic to 
apprehension to arguments continue to elicit increased 
sweating over a long time period of 1-1~ hours (57,58). 
Simultaneous emotional and thermal stimuli produce 
an additive effect on sweat output. Minor emotional 
stimuli are greatly magnified at higher temperatures, 
resulting in an increased axillary sweating rate (58). 
3. Diet and liealth. Higher metabolic rates, 
whether caused by fever, thyroid function, or rich, spicy 
foods, cause greater heat production and, in turn, 
increased sweating (58,59). A low salt diet of 100 
mg/day shows a 20-25% decrease in sweat output compared 
to a 40 g/day salt intake diet (58). Water intake has 
little effect on sweat rate, but a substantial loss of 
water causes a substantial loss of sodium chloride (29,60). 
The response of the sweat glands to a given stimulus, 
whether it be thermal, emotional or gustatory, is a 
function of the three factors, mainly because it is related 
to the acetylcholine produced (61). 
4. Other factors. Body posture affects the sweat 
rate. If a subject is in a sitting or reclining· position 
for an extended time period, the body adjusts and the 
sweat rate decreases. If there is a sudden change in trunk 
( 
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position, there is a substantial increase in sweat 
rate (11,58). A dramatic increase in sweat rate and 
volume occurs with muscular exercise; this increase is 
dependent upon the preexercise sweating rate (62). 
There are conflicting reports about the effect of 
dominant-handedness on sweating. In one study, 7ff'fe of the 
left-handed subjects and 60% of the right-handed subjects 
had a greater sweating rate on the side opposite the 
dominant hand (63). Other studies indicate that the 
dominant-handed side sweats more (24). ~here is a significant 
variation in right to left axillae sweat ratios from day to 
day in the same individual (9,11). Generally, the side with 
greater sweat volume remains the same. 
Axillary sweat collection devices can greatly alter 
the sweating rate. ~b.e force of a vial pressed against 
a flat collection pad reduced sweating rate (58). A 
comfortable, yet snugly fitting collection device is 
necessary to insure proper sweat collection with no chance 
of sweat evaporation. 
G. Control of Perspiration 
1. History. Throughout history man has searched for 
ways to inhibit body odor and perspiration with perfumes and 
cosmetics. ·· From ancient Egyptian times to the 1800s bath 
oils and perfumes were used to scent the body. In 1888, 
the first trademarked deodorant, Mum, a perfumed wax base 
to plug pores, was marketed. In 1914, the first commercial 
( 
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aluminum chloride-based deodorant, Odo-Ro-No, was 
produced. In addition to its deodorant properties, it 
was later discovered to have excellent antiperspirant 
activity. Since then, researchers have tested various 
chemicals to help stop odor and wetness. The introduction 
of aluminum chlorhydrate in 1947, an antiperspirant agent 
that was non-irritatinf? and minimized fabric damage, 
accelerated consumer use of antiperspirant/deodorant 
products. In 1950, hexachlorophene was added to 
antiperspirant formulations to enhance their anti-
bacterial properties, but extensive research on the brain 
damaging effects of hexachlorophene resulted in termination 
of its use a decade later. 1'b.e introduction of roll-on 
lotions in 1950 and aerosol antiperspirants in 1968 
caused the rapid expansion of the antiperspirant market. 
A decade later the controversy over the damage to the 
ozone layer caused by fluorocarbons in aerosols prompted 
their phase out. 1nis action, reported in the ~lay 1977 
Federal Register, redirected antiperspirant manufacturers' 
attention to the familiar roll-on and stick vehicles. In 
1975, manufacturers began the shift from aerosols to 
manual pump sprays. Today, antiperspirant manufacturers 
are evaluating the safety, toxicity, and efficacy of both 
their well-established and ' experimental products as 
directed by the 1972 Food and Drug Ad.ministration's 
Over-The-Counter Drugs Antiperspirant Panel. This panel 
( 
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will have a major impact on future trends in the 
antiperspirant market (21,22,64-?0). 
2. Mechanism of action of antiperspirants. Personal 
hygiene, deodorants, and antiperspirants are the main 
methods of controlling the objectionable aspects o! 
perspiration--offensive odor and excessive sweat gland 
secretions. 
Deodorants help control body odor by masking it and/or 
reducing its intensity. lbey conform to the Food, Drug, 
and Cosmetic Act's definition of a cosmetic as "• • • 
article intended to be rubbed, poured, sprinkled, or 
sprayed on • • • the human body • • • for cleansing • 
(or) ••• promoting attractiveness •• •" (?1). 
Deodorizing agents for the human body include 
an 
• • 
antibacterials such as neomycin, neutralizing agents such as 
sodium bicarbonate, and astringents such as aluminum 
chloride (55,72-74). 
Antiperspirants control and reduce the flow of 
perspiration. Plechner and deNavarre (75,?6), classify 
antiperspirants as drugs because of their anhidrotic 
action. Antiperspirants also conform to the Food, Drug, 
and Cosmetic Act's definition of a drug, "• •• articles 
intended to affect the structure or any function of the 
body of man ••• " (71). 
The astringent aluminum salts contained in the 
majority of commercial antiperspirants possess both 
( 
15 
deodorant and antiperspirant actions. Their deodorant action 
involves their antibacterial and chemical properties. The 
acid pH of aluminum compounds, which inhibits bacterial 
decomposition of sweat secretions, prevents odor development; 
and the chemical combination of the aluminum salts and the 
odoriferous substance neutralizes the odor (36,77,78). The 
antiperspirant action of aluminum salts is still disputed. 
They may act ··directly on the sweat gland, or form a plug or 
block in the sweat duct, or involve the electro-physiological 
potential along the sweat duct (?9,80). Papa (81) studied 
the alteration of permeability of eccrine sweat ducts treated 
with aluminum chloride. He concluded that the aluminum salt 
increases the transductal absorption of sweat. Hermann's 
and Sulzberger's theory (82) is the one that is recognized 
most widely. They observed that antiperspirants produce an 
inflammatory reaction accompanied by swelling and an expansion 
of the horny layer around the sweat duct causing its 
constriction and reducing sweat delivery to the skin 
surface (79). 
3. Antiperspirant agents. A variety of effective 
topical antiperspirant agents have been tested. Anti-
cholinergics such as scopalamine esters are very effective 
anhidrotics, but have toxic effects when used on a 
long-term basis (41-46). Formaldehyde and aluminum salts 
irritate the skin and damage clothing (14,83). Zirconium 
was very popular in the 1950s, but frequent incidences of 
( 
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granulomas were reported (83-85). 
Aluminum chlorhyd.rate is the major antip~rspirant 
agent used in today's commercial products. It is a basic 
aluminum chlorhydroxide complex with an atomic ratio of 
aluminum to chloride of 2:1 as compared to 1:~ in the aluminum 
chloride. A 20% w/w solution has a pH of 4.2 compared to 
aluminum chloride's pH of 2.0-2.5 (Table 1). This higher 
pH, a result ' of the large proportion of hydroxyl groups, 
reduces skin irritation, minimizes clothing destruction, 
is consistent with the skin's acid mantle, and prevents 
rapid hydrolysis of the antiperspirant agent. This provides 
pH stability over a wide range of concentrations as 
illustrated in Figure 2 (86). 
Aluminum chlorhydrate is very water soluble. A 
50% w/w solution in water is clear, colorless, slightly 
viscous; it is soluble with ethyl alcohol, making it ideal 
for use in the manual pump sprays. 
Aluminum chlorhydrate is available in a variety of 
particle sizes making it adaptable for varying uses and 
vehicles. '..lb.e impalpable grade of solid aluminum 
chlorhydrate is designed for aerosol and suspensoid stick 
application (87). Sodium aluminum chlorhydroxy lactate, 
pH 8.5, was developed for use in sodium stearate based 
sticks and systems requiring buffering (88). Aluminum 
chlorhydroxide-proplyene glycol complex is being used more 
in aerosols, pump sprays, and stick antiperspirants. It 
( 
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Formula 
pH 
Al:Cl 
TABLE 1 
COMPARISON OF THE CHEMICAL PROPERTIES 
OF 
ALUMINUM CHLORIDE AND ALUMINUM CHLORHYDRATE 
ALUMINUM CHLORIDE 
Al 013 
2.00 - 2.50 
1:3 
17 
ALUMINUM CHLORHYDRATE 
Al2 (OH)5 Cl 
4.00 - 4.25 
2:1 
18 
pH 
5.0 
4.0 
1.0 
5 10 15 20 25 30 35 
% Concentration of Salt 
Figure 2. Comparison of pH values of aluminum 
chlorhydrate, aluminum sulphatet and 
aluminum chloride solutions (86;. 
( 
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is soluble in both water and anhydrous alcohol up to 
concentrations of at least 50% (69,89). 
Aluminum chlorhyd.roxy allantoinate, "a stable, white, 
odorless powder which combines the antiperspirant and 
astringent bacteriostatic properties of aluminum 
chlorhyd.rate with the therapeutic and cosmetic properties of 
allantoin," (90), is used in conjunction with aluminum 
compound antiperspirants. It is compatible in a pH 
range of 1-6.1. It is employed in concentrations from 
0.2-0.3% for its anti-irritant, keratolytic, bacteriostatic, 
astringent, moisturizing, anti-pruritic, and healing actions. 
It has been proven beneficial in preventing or alleviating 
dermatitis associated with antiperspirant products (20). 
Alcohol-soluble aluminum chlorhydroxy allantoinate is 
a molecular form of the allantoin complex used in concen-
trations from 0.2-0.5% in hydroalcoholic and aerosol 
formulations (90). 
A modified form of aluminum chlorhydroxy allantoinate 
is available for use as the single active ingredient in 
concentrations from 6-200fe in antiperspirant lotions and 
creams. A 200fe solution of modified aluminum chlorhydroxy 
allantoinate has a pH of 3-5 and contains 19.S°fe aluminum 
chlorhydroxide as an active antiperspirant ingredient and 
0.2"fe allantoin complex for its therapeutic and cosmetic 
effects. Alcohol-soluble, modified aluminum chlorhydroxy 
allantoinate is employed in concentrations from 6-10"fe in 
{ 
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aerosol antiperspirants (20). 
H. Antiperspirant Formulation and Vehicular Considerations 
It is generally recognized that aluminum chlorhydrate 
effectively inhibits perspiration, but its activity is 
influenced by formulation excipients (e.g., vehicle), mode 
of application, concentration of agent, and the amount of 
antiperspirant applied (4,6,9,91). In addition, vehicle 
plays an important role in consumer acceptability. A 
vehicle that is physically and chemically compatible with 
the antiperspirant agent, is dermatologically safe, and 
results in a cosmetically acceptable and elegant product, 
is necessary. 
A number of !actors must be considered when !orm-
ulating antiperspirants. Aluminum salts other than the alu-
minum chlorhydroxide complexes are sufficiently acidic to 
cause a salting out effect of the metal ions; they are 
rapidly hydrolyzed, and will react readily with soap bases 
such as free stearic acid to form an undesirable product. 
To maintain their antiperspirant efficacy and minimize 
skin irritation, a pH consistent with the acid mantle of 
the skin is sought, and the addition of buffers such as 
urea are necessary. The use of aluminum chlorhydroxide 
complexes have solved many of these problems. 
Marketed antiperspirant vehicles include creams, 
roll-ons, sticks, aerosols, and pump sprays. 0reams and 
( 
21 
roll-ons are oil-in-water or water-in-oil emulsions with the 
active ingredient dissolved in the aqueous phase. The 
addition of nonionic surfactants such as Tween 60 and 
Arlacel 60 or Arlacel 165 emulsify and thicken the product. 
These surfactants are nonirritating to the skin and are 
compatible with aluminum salts. By varying the concentrations 
of additive ingredients such as Veegum, cetyl alcohol, or 
spermaceti, the viscosity and consistency of the product 
can be altered. Glycerin may be added for emolliency and to 
prevent the formation of aluminum crystals (92-94). 
To maintain antiperspirant efficacy in a 
cosmetically suitable stick, the impalpable grade of 
aluminum chlorhydrate is suspended in a wax base, or the 
aluminum chlorhydroxide-proplyene glycol complex is 
dissolved in a stearamide-based stick (95,96). An 
alcoholic diluent and neutral, acidic-aluminum-compatible 
gelling agents, such as stearamide and sucrose distearate, 
are the building blocks of the stick. Isopropyl myristate 
is added for emolliency. Volatile silicones are added to 
reduce tackiness, drag and drying time (96,97). 
Alcohol-soluble forms of aluminum chlorhydroxide 
such as aluminum chlorhydrate, 50'~ w/w solution, or 
aluminum cnlorhydroxide-propylene glycol are used in the 
commercial manual pump spray antiperspirants. The 
alcohol-based manual pump sprays require the addition of 
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valve lubricants, such as stearic acid or Arlamol E, to 
prevent aluminum salt crystallization which causes valve 
clogging and spray sputtering. Arlamol E and volatile 
silicones are also added for emollience and reduction of 
tackiness and drying time. Powder-in-oil suspensions for 
use in pump sprays are being tested (96,98,99). 
Perfumes, emollients, thickeners, coloring agents, 
and other component ingredients are frequently added to 
enhance product appearance and application. Aerosols re-
quire different formulation considerations. They are 
powder-in-oil suspension concentrates pressurized with a 
propellant. lb.e active ingredient is suspended in the 
powder phase, while the oil phase is composed of high 
molecular weight carboxylic acid esters and perfume oils. 
Epoxy linings prevent the aluminum salt froc corroding 
the metal containers. Aluminum chlorhydroxide-propy~ene 
glycol complex has proven advantageous for use in aerosols 
because it is effective, safe, and may be packaged in 
low-cost metal containers with fluorocarbon propellants 
(70,a9,100,101). 
I. Assessing Antiperspirant Efficacy 
1. In vitro. In vitro methods are used for 
preliminary study of a potential antiperspirant's 
activity. Govett and deNavarre (14) developed the 
protein precipitation test, a qualitative or 
( 
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semi-quantitative test for astringency. One cc of 
astringent salt solution is added to a 1:1 mixture of egg 
albumin and distilled water. The rate of protein precipita-
tion, the nature of the precipitate, and solubility 
characteristics over a 12-hour period of various 
astringents are then evaluated subjectively. Protein 
precipitation testing confirms the superiority of 
aluminum chl.orbydrate over other aluminum salts as a protein 
precipitant, despite its higher pH. 
A standardized, reproducible frog skin test was 
developed by Govett and deNavarre (14) to measure 
antiperspirant activity. Frog skin is treated with varying 
concentrations of astringent salt solutions. 'lb.e area of 
skin shrinkage and decrease in water permeability of the 
frog's skin is used to measure the astringent action of 
the solutions. Christian et al. (16,18) expanded this test 
by evaluating the effect of antiperspirant preparations on 
the permeability of sodium and iodide ions on frog 
membranes. The extent of iodide penetration was measured 
by radioactive tracer technique. 
2. In vivo. Pilocarpine-induced sweating in mouse 
and rat foot pads has been used for testing antiperspirant 
activity (15). However, animal eccrine sweat glands differ 
histologically from man's (11,102), limiting animal testing 
of antiperspirants to measuring irritant potential of the 
agent. 
( 
( 
( 
24 
Human testing is necessary for assessing efficacy and 
consumer acceptance of a finished antiperspirant product. 
The quest !or knowledge of sweat gland function and 
antiperspirant efficacy has resulted in a variety o! 
techniques for visualizing, assessing, and collecting 
sweat (103). 
Wada and Taltagaki (104) developed a colorimetric 
.. 
technique that permits visualization of sweat patterns on 
the skin. Skin surfaces painted with a starch-alcoholic 
iodine mixture produce a characteristic blue-black color in 
distinct patterns corresponding to the presence of active 
sweat pores as moisture reaches the skin surface. Papa 
(105,106) modified their mixture with a castor oil suspension. 
This prevented environmental moisture from interfering with 
the results while permitting the presence of sweat droplets 
to be visualized. 
Visual techniques are used mainly in studying sweat 
gland activity (59,10'7.). To measure antiperspirant 
activity a reduction in magnitude of color relative to an 
untreated area is evaluated visually. Sweat patterns and 
numerical dot counts taken by blotting paper towels or 
pressing ping-pong balls against the tested area have been 
adapted to .semi-quantify this method (106,108). However, 
this method does not take into account the size of the 
sweat droplets or the sweat intensity (9). 
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Continuous recording techniques have been used to 
quantify sweat production; electronic hygrometers sense and 
record perspiration electronically. While axillary moisture 
is continuously removed by a constant flow of gas, an 
electronic recording device automatically records and plots 
the sweat ratios or perspiration rates. This procedure 
eliminates variables involved in sweat collection, such as 
excessive subject movement (the subject is wired and strapped 
with electronic devices in a thermal chamber). Positioning 
of the moisture sensing element over the small test area is 
critical in obtaining reproducible results. Tb.is method is 
not favored for testing in an area of uneven distribution o! 
sweat glands such as the axilla. It has proven useful in 
testing on the forearm, an area with an even sweat gland 
distribution unaffected by reflexes (11,17,109,110). 
In spite of the possible errors inherent in the 
gravimetric technique, such as evaporative loss from pads, 
lack of distinction between sweat and sebum, positional 
variation of pad in the axillary vault, and environmental 
and emotional factors affecting human sweating, it is the 
most widely used method for testing antiperspirants (4,5, 
9,11,12,23-27,38,103). Since the aim of an antiperspirant 
is to cont rol perspiration in humans for everday use in all 
types of environments and situations, the gravimetric 
technique's antiperspirant efficacy results most closely 
resemble consumer use of an antiperspirant product. 
( 
26 
This method is simple, inexpensive, and may be used to test 
a large number of subjects simultaneously, whether in 
humidity controlled rooms or at ambient temperatures. It 
is best adapted for axillary sweat collections (6,24). 
Sweat is collected on tared absorbent pads or silica 
gel tins !itted snugly to the axillae. Arter a given period 
or time the pads or tins a:re removed and weighed for 
perspiration- ~ach subject acts as his own control: one 
axilla is treated with antiperspirant and the other axilla, 
the control, is not treated. 
Sweat collections carried out in controlled 
temperature rooms of 100°F and 35°~ relative humidity are 
preceded by a 40-minute conditioning period in the hot room 
~ hese during which the panelists hold pads to their axillae. 
pads are discarded, since extremely erratic results in 
sweat weight are obtained. during this time. This is 
followed by two or three 20-minute collection periods 
using tared pads. This process may be repeated for 2 to 5 
days; ratios are then calculated and averaged (6,11,23-27). 
Under ambient conditions, panelists tape or harness 
tared pads for a minimum of three hours during a regular 
work day (6,9,23-25). This process is repeated for 2 to 5 
days. In both cases, panelists are requested to remove 
axillary hair and to abstain from personal antiperspirant 
products for a minimum of one week prior to testing and for 
the duration of the test. Some investigators have allowed 
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the use o! deodorant products !or personal comfort (9). 
Sweat collection results are evaluated statistically by 
the ratio method or by using a geometric mean. In the ratio 
method, both axillae serve as controls for a pretest sweat 
collection period. A pretest perspiration ratio (PR) is 
calculated as 
• PR (23). 
A treatment period is then conducted to obtain a sweat 
ratio of treated a.xilla to control a.xilla. Using an 
arithmetic mean, the pretest and posttest ratios are 
averaged and antiperspirant efficacy is calculated as 
( treatment week ratio ) 1 
- ratio prior to treatment x 100 • percent sweat 
reduction (103). 
In 1974, Wooding (26) used the geometric mean in a 
Sides Subjects Effects Model and produced comparable 
antiperspirant efficacy results with the ratio method. His 
model eliminated the need for pretest collection periods, 
making it a simple, inexpensive, and convenient method for 
obtaining antiperspirant efficacy data. Other researchers 
(4,9,57) have adopted this method to determine antiperspirant 
efficacy. Perspiration weights in milligrams are trans-
formed to natural logarithms before statistical analysis. 
The treatment mean (T') and control mean (C') are then 
backtransf ormed to milligrams to calculate the percent 
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sweat reduction. 
Percent Sweat Reduction• (1 - antilog(T' - C')) x 100 (4) 
J. Previous Studies 
The FDA OTC panel directive to review topical drugs 
as antiperspirants and their component ingredients !or 
their sa!ety, toxicity, and efficacy (4,21) has illuminated 
the paucity of information regarding vehicular effects on 
antiperspirant efficacy. Review articles by Uttley (103), 
Bakiewicz (11), and Jungermann (6) provide an excellent 
source of early antiperspirant efficacy studies. However, 
these studies have been mainly concerned with the efficacy 
of the antiperspirant agent itself (10-19). The majority of 
efficacy studies use modifications of Fredell and Read's (23) 
gravimetric technique introduced in 1951. Recent tests 
use the same sweat collection procedure, but efficacy 
calculations are shifting from their arithmetic mean and 
adapting Wooding's (26) geometric mean of calculating 
percent sweat reduction. 
Majors and Wild (24) observed the influence of 
sweating rate, sweat collection conditions, and methods 
of data analysis on antiperspirant effectiveness. Using a 
gravimetric technique procedure and a ratio method of 
calculation~ they concluded that: sweat from the dominant 
( 29 hand axilla is greater; efficacy results are similar 
whether taken in a humidity controlled room or during ambient 
conditions; axillary sweating ratios are more uniform than 
sweating rates from the same panelist (marked variation of 
response to antiperspirant application existed among 
panelists), and formula additives possibly acting as 
irritants to the axilla affect perspiration output and 
antiperspira1l.t effectiveness. 
Steed (9) collected sweat in silica gel moisture 
absorbing tins strapped to the body side of the axilla under 
normal conditions of use. He evaluated three formulations, 
one comprised of 25°fe aluminum chlorhydrate in an aqueous 
solution thickened with hydroxyethyl cellulose, the second 
an 11% aluminum chlorhydrate water-in-oil emulsion aerosol, 
and the thirdt . 3.~~ aluminum chlorhydrate suspended in a 
commercial aerosol. Each participant was arbitrarily 
designated a treatment a.xilla to which he applied an unknown 
amount of test antiperspirant. Test data were calculated 
using a geometric mean. Percent sweat reduction results 
exhibited the superiority of the water-in-oil emulsion aerosol. 
He also observed considerable variation in response among 
individuals. 
Jung~rmann (6) compared results of antiperspirant 
efficacy under normal activity and controlled thermal 
environment. He evaluated a variety of antiperspirant 
agents in various vehicles for antiperspirant and 
deodorant efficacy, safety, staining potential, and 
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cosmetic acceptability. Using the ratio method and Student 
t-test he found no significant difference among the active 
ingredients' effectiveness in the same formulation, but did 
notice a difference in activity among vehicles and 
concentrations. He concluded that a controlled thermal 
environment places stress on the panelist resulting in poor 
experiment reproducibility, while normal conditions provide 
reproducible.results and more closely approximate consumer 
use and opinions of an antiperspirant. 
Wooding et al. (19,26) are innovators of experimental 
design and data analysis procedures associated with 
gravimetric antiperspirant tests. Using a Latin Square 
design, Wooding et al. (19) applied similar concentrations 
of four different antiperspirant agents in aqueous solutions 
to the backs of panelists and collected sweat under normal 
temperatures in silica gel tins. The results indicated 
that the balanced design and analysis was satisfactory, 
statistically sound, and useful in interpreting anti-
perspirant efficacy data. A decade later Wooding and 
Finklestein (26) developed a Sides Subjects Effects 
Model (SSll-1) using a cross-over design. They compared 
efficacy results under thermal and ambient temperatures 
using the arithmetic mean of the ratio method and the 
geometric mean of their method. The SSEM not only 
gave comparable results to the well-established ratio 
method, but also eliminated the need for pretest ratios. 
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O'Malley and Christian (17) used a continuous 
recording method to evaluate perspiration properties of 
six commercial antiperspirant agents and three commercial 
bases in the forms of a stick, a cream, and a lotion in com-
parison with a 24% w/w aluminum sulfate solution. All 
preparations were applied to the subjects' forearms, and 
the subjects were exposed to varying thermal conditions. 
A ratio method of calculation indicated that aluminum 
methionate was the most effective agent and that vehicle 
did not affect antiperspirant efficacy. 
Bretschneider et al. (4) used a gravimetric 
axillary procedure in a humidity-controlled room to 
evaluate efficacy of aluminum chlorhydrate type 
ingredients. Antiperspirant efficacy was calculated using 
the geometric mean. They tested varying aluminum to 
halide ratios, multi-ingredient formulations, varying 
concentrations of single-ingredient formulations, and 
aqueous versus hydroalcoholic dose forms for efficacy. 
Definitive results were obtained that showed an increased 
effectiveness of aqueous vehicles and that optimum 
concentration efficacy reached a maximum of 15°fe aluminum 
chlorhydrate rather than a plateau. 
III. METHODOLOGY 
A. Materials 
The following chemicals were used in this study and 
have been classified by lot number and manufacturer. 
Glycine, (lot# G620-1)1 
Arlacel 60, sorbit~ monostearate, (lot# 0602067)2 
Cetyl Alcohol, N. F., (lot# ?5039000?)2 
Spermaceti, U. S. P., granular, (lot# 0608196)2 
Titanium Dioxide, u. s. P., powder, (lot# C612248)2 
Amerchol CAB, (lot# 153)3 
Amerchol L-101, multisterol extract, (lot# 932)3 
Modulan, acetylated lanolin, (lot# 351)3 
Solulan 16, ethoxylated (16) lanolin alcohol, (lot# 1278)3 
Solulan 98, acetyl p. o. e. (10) lanolin alcohol 
complex, (lot# 363)3 
Glycerine, 96%, Crystal White, (lot# 78-206)4 
1. Aldrich Chemical Co., Inc., Milwaukee, Wisconsin. 
2. Amend Drug and Chemical Co., Irvington, New Jersey. 
3. Amerchol, Edison, New Jersey. 
4. Colgate-Palmolive Co., New York, New York. 
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Crodamol IPH, isopropyl myristate, (lot# 331)5 
Crodesta A 10, acetylated sucrose distearate, (lot# 3600403-2)5 
Procetyl AWS, alcohol and water soluble cetyl alcohol, 
(lot# 66)5 
Super Hartolan, lanolin alcohol, (lot# 428?0)5 
Gulf ax, paraffin, (lot# C211K-I-LP)6 
Arlacel 165, glycerol monostearate and polyoxyethylene 
stearate, .. (lot# 1855)7 
Arlacel 186, glycerol fatty acid ester, (lot# 391)7 
Arlamol E, polyoxypropylene 15 stearyl ether, (lot# 4453B)7 
Myrj 52, polyoxyl 40 stearate, U. s. P., (lot# 280)7 
Tween 60 SD, sorbitan monostearate, (lot # 1153)7 
G-2162, polyoxyethylene (25) propylene glycol stearate, 
(lot# 119)7 
p-Dioxane, (lot# 64)8 
Veegum, colloidal magnesium aluminum silicate, (lot# 0612248)9 
Chlorhydrol, 5C1fo w/w Solution, aluminum chlorhydroxide 
complex, (lot# 6115)10 
5. Croda, Inc., New York, New York. 
6. Gulf Oil Corp., Houston, Texas. 
?. ICI Americas Inc., Wilmington, Delaware. 
8. Matheson, Coleman, and Bell, E. Rutherford, New Jersey. 
9. R. T. Vanderbilt Co., Inc., New York, New York. 
10. Reheis Chemical Co., Berkeley Heights, New Jersey. 
MicroDry, Ultrafine, impalpable grade of solid aluminum 
chlorbydroxide complex, (lot# 5783)10 
Rebydrol, aluminum chlorhyd.roxide-propylene glycol complex, 
(lot # 822)10 
Candelilla Wax, (lot# TL83074)11 
Carnauba Wax Yellow #1, ~lot# 65204)11 
Fluid Silicones 200, 1000· cps, (lot# AA6045)11 
Propylene Glycol, U. S. P., (lot# S-353998)11 
Ozokerite Wax, white, (lot# N?0970)11 
Sodium Lau.ryl Sulfate, dental grade, (lot# 0713284)11 
Tenox BHT, (lot# 101267)11 
Stearic Acid, U. s. P., (lot# F-1-0562)11 
Alcohol soluble aluminum chlorhydroxy allantoinate 
modified12 
Alcohol soluble aluminum chlorhydroxy allantoinate 
molecular12 
Aluminum chlorhydroxy allantoinate12 
Aluminum chlorhydroxy allantoinate modified12 
10. Reheis Chemical Co., Berkeley Heights, New Jersey. 
11. Ruger Chemical Co., Irvington, New Jersey. 
12. Schuylkill Chemical Co., Philadelphia, Pennsylvania. 
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Glassware and common laboratory equipment were supplied 
by the College o! Pharmacy of the University o! Rhode Island. 
Additional supplies and their manufacturers are: 
Cotton tipped applicators, 6", (lot# 22-9186), 
ABCO Distributors Inc., Milwaukee, Wisconsin. 
Dermicel Hypoallergenic Cloth Tape, 2" by 10 yds., Johnson 
and Johnson, New Brunswick, New Jersey. 
Ivory Soap, Proctor and Gamble, Cincinnati, Ohio. 
Surgex Hair Remover Cream, Cooper Scientific Corporation, 
Watertown, Massachusetts. 
Webril Handi Pads, Kendall Fiber Products Division, 
Walpole, Massachusetts. 
Ziploc Storage Bags, 17.8 cm by 20.3 cm by 1.75 mil, 
The Dow Chemical Company, Indianapolis, Indiana. 
B. Methodology 
1. Antiperspirant formulations. To limit the 
variables in this study, an effective active ingredient 
was selected to be incorporated in four different vehicles 
after two antiperspirant agents were tested for solubility 
and physical and chemical compatibility. 
The active agents, modified aluminum chlorhydroxy 
allantoinate and aluminum chlorhydrate, were tested for 
solubility ·and compatibility in four widely used vehicular 
forms, a cream base, an aqueous roll-on lotion, a 
solid stick, and an alcohol base such as one used 
in the manual pump sprays (Appendix A). All products 
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were formulated by the researcher to ensure experimental 
control over concentrations o! active ingredients and 
materials used for component ingredients. 
Preliminary dose form and solubility studies were 
performed with these agents in varying concentrations of 
byd.roalcoholic, propylene glycol/water, propylene 
glycol/alcohol, and dioxane/water solutions. Noting the 
concentrations of agent necessary for antiperspirant 
activity in compatible dose forms led to the selection of 
20'4 aluminum chlorbyd.rate as the antiperspirant agent and 
0.25% aluminum chlorhydroxy allantoinate for its therapeutic 
and cosmetic properties. 
Three different grades of aluminum chlorhydroxide 
complex--Chlorhydrol, 5CY14 w/w solution, MicroDry, 
Ultra.fine, and Rehydrol--were tested in suitable dose 
forms. Chlorhydrol, 50% w/w solution was employed in 
concentrations of 40'4 (92-94) in preliminary formulations 
of creams, lotions, and alcohol based solutions (Appendix A). 
Twenty percent MicroDry, Ultra.fine was incorporated directly 
into a variety of solid sticks. Since Rehydrol (89,111) is 
equivalent to 75% by weight of the aluminum chlorhydroxide 
complex, 26.?~ Rehyd.rol was used in formulating sticks and 
alcohol-based solutions to maintain an equivalent amount of 
active ingredient with the preparations containing 
Chlorhyd.rol, 501G w/w solution. For its beneficial 
therapeutic and cosmetic properties, 0.25% aluminum 
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chlorhydroxy allantoinate (20,90) was incorporated into 
preliminary formulations of creams and lotions, and the 
alcohol-soluble form was used in the stick and alcohol 
solutions. 
Modification of established formulations (92-98) 
was necessary to prepare a simple, yet cosmetically 
acceptable vehicle. All preliminary formulations were 
tested and compared for physical and chemical compatibility, 
stability, and consumer acceptability. One product from 
each vehicular form was selected for use as the test 
antiperspirant. Several cream antiperspirants were 
formulated. Most were similar in composition to the 
test cream antiperspirant. Forty percent Chlorhydrol, 
50% w/w solution, and 0.25% aluminum chlorhydroxide 
allantoinate were incorporated in a cream base. The 
test cream (93) antiperspirant contained 
%, weight 
A. Cetyl alcohol •••••••••••••••••••••••••••••••••• 5.00 
Arlacel 165••••••••••••••••••••••••••••••••••••5.00 
B. Distilled water•••••••••••••••••••••••••••••••49.?5 
Aluminum chlorhydro:xy allantoinate ••••••••••••• 0.25 
Chlorhydrol, 50'fe w/w solution ••••••••••••••••• 40.00 
Phase A contained cetyl alcohol for stiffening, 
consistency, and texture. Arlacel 165 
100.00 
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served both as emulsifier (HLB • 11) and a thickener (112). 
This phase was heated slowly with constant stirring to 
?0°0. The water phase, B, consisting o! suitable 
concentrations of the active ingredient and the allantoin 
complex, was heated to 72-C to allow for rapid cooling. 
B was added to A at the same temperature with constant 
stirring to permit proper emulsification. The emulsion 
was stirred rapidly until it set at about 40°0 and then 
packaged in opaque ointment jars. 
This cream was white, fluffy, easy to apply, and 
quick-drying. An application o! 500 mg of the antiperspirant 
cream to each axilla provided 100 mg of active ingredient 
in solution. 
The test lotion antiperspirant contained 
%, weight 
A. Veegum•••••••••••••••••••••••••••••••••1.00 
Water, distilled•••••••••••••••••··~··50.75 
B. Arlacel 165 •••••••••••••••••••••••••••• a.oo 
c. Chlorhyd.rol, 5o:'fe w/w solution ••••••••• 40.00 
Aluminum chlorhydroxy allantoinate ••••• 0.25 
100.00 
Veegum was added slowly with continual agitation to water 
at room temperature until a smooth mixture resulted. The 
mixture wa$ then heated to 70°0. Veegum is frequently 
used in roll-on lotions to increase the viscosity. It 
also is used as an emulsion stabilizer. Arlacel 165 was 
heated separately to 75°0, then added to A with agitation 
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and mixed while cooling to 50°0. The allantoin complex was 
dissolved in Chlorhydrol, SO'fe w/w solution at 50°0 to form 
a clear solution. This solution was added to the above 
mixture and mixed constantly until it cooled to 38°0. 
This aqueous lotion provided 100 mg of active 
ingredient in solution per 500 mg of lotion. The cream and 
lotion both contained Arlacel 165. In the cream, the Arlacel 
165 was used' to emulsii'y the oil and water phases, while in 
the lotion, it was used as a thickener and stabilizer. A 
trial test showed that the lotion could be applied 
successfully from a roll-on applicator. This white, viscous, 
quick-drying antiperspirant was considered the most elegant 
and cosmetically acceptable vehicle by the volunteers. 
Stick formulations introduced a variety of formulation 
problems. The acidic aluminum salts are not suitable for 
use in a sodium stearate-based stick. Stearamide, used 
frequently as an antiperspirant stick building block with 
great success in industry, was unobtainable. Therefore, a sus~ 
pensoid stick containing MicroDry, Ultrafine was formulated. 
A solid stick antiperspirant (97) that was quick-drying 
and of suitable consistency for axillary application contained 
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A. Crodesta A 10••••••••••••••••••••••••••••••••••••••••38.5 
Procetyl AWS••••••••••••••••••••••••••••••••••••••••••9.6 
B. MicroDr,y, Ultra.fine••••••••••••••••••••••••••••••••••38.5 
Alcohol soluble aluminum chlorbydroJty allantoinate •••• 0.5 
c. Crodamul IPM•••••••••••••••••••••••••••••••••••••••••12.9 
100.0 
Phase A was ~issolved at 70°C and B was added with constant 
stirring until a uniform mixture resulted. C was added with 
constant stirring until uniform. The mixture was poured into 
2-gram suppository molds to cool. Crodesta A 10, the 
lipophilic gellant, provided excellent structure and slip 
to a solid stick. Crodamul IPM and Procetyl AWS served as 
emollients and to reduce tackiness. The latter was also 
used to improve water dispersability of the antiperspirant 
agent and act as a dispersing agent for the active in-
gredient upon application (113). In order to provide a 
smaller sample application size, a concentration of 38.5"fe 
MicroDry, Ultrafine was necessary. Thus, a solid stick of 
260 mg imparted 100 mg of active ingredient. The amount of 
active ingredient was consistent with the other three dose 
forms. 
Rehydrol is often used by the industry as an anti-
perspirant agent in pump sprays, because it is effective, 
quick-drying, and causes a minimum amount of tackiness. 
It may be used in alcoholic or hydroalcoholic solutions. 
Stearic acid is generally added to alcoholic solutions 
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to prevent gellation and to lubricate the pump spray valve 
(96). However, to maintain allantoin complex compatibility, 
a hydroalcoholic solution was needed. So, to maintain 
consistency in all the vehicles, Chlorhyd.rol, 50'~ w/w 
solution was selected as the active ingredient in the 
alcohol-base dose form. Chlorhyd.rol is used in many 
commercial hydroalcoholic solutions (95,96,98,99). 
%, weight 
A. Alcohol •••••••••••••••••••••••••••••••••••••••••••• 50.00 
Arlamol E ........................... •·•• •·•·• .............. 5.00 
B. Chlorhydrol, 50'fo w/w solution •••••••••••••••••••••• 40.00 
Alcohol soluble aluminum chlorbydroxy allantoinate •• 0.25 
Water, distilled••••••••••••••••••••••••••••••••••••4.75 
100.00 
A and B were dissolved separately at room temperature. B 
was added to A with constant agitation until dissolved. 
Arlamol E functioned as a solvent, emollient, and valve 
lubricant. This clear hydroalcoholic test antiperspirant 
imparted 100 mg of active ingredient per 500 mg of anti-
perspirant applied. The solution was shown to be suitable 
for use in a commercial manual pump spray. 
Perfumes and coloring agents were not incorporated 
into any of the antiperspirant formulations. This 
eliminated ·the possibility of allergic reactions, 
dermatological irritations, physical and chemical 
formulation incompatibilities, and other variables 
associated with perfumes and coloring agents. The 
( 
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volunteers preferred unscented commercial antiperspirants 
for their daily use prior to the test. 
Preservatives were deemed unnecessary because the 
ingredients used in formulations are extremely stable. These 
formulations did not separate, cream, or show any other 
instability or aging signs during their six-month shelf 
life. 
2. Test procedure. Four vehicles containing 
aluminum chlorhydrate were compared for efficacy by a 
well-recognized gravimetric procedure (4-6,9-12,23-27, 
38,55,57) during a normal work day in each subject's 
normal work environment. 
A detailed report of the proposed project, its 
objectives, methods, and potential adverse effects was 
submitted for approval to both a University Human Studies 
Committee and an Institutional Review Board (Appendix B). 
Following the guidelines established by these committees, 
volunteers were asked to maintain normal bathing habits 
with the exception of an axillary hygiene regimen. The 
axillary hygiene regimen consisted of abstaining from 
non-test antiperspirant/deodorant use during the test 
period, removal of axillary hair with Surgex (a surgical 
depilatory) three days prior to each sweat collection 
period, and washing the axillary area with Ivory Soap 
and water only. Each subject was supplied with the necessary 
materials by the researcher. 
, ( 
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• Sweat was collected on tared adsorbent Webril pads 
taped snugly to the axillae with Dermicel cloth hypo-
allergenic tape. Webril pads are made o! 100'~ sort, lint-
less cotton. They have no binder and have a pH of 7. They 
are used frequently in surgical procedures, plate, press, 
and camera work, and in gravimetric antiperspirant 
tests (6,12,~3,24,114). A 4-ply Webril pad was sewn onto a 
2-by-4-inch piece of Ziploc. The Ziploc backing ensured the 
retention of sweat on the pad and easy removal of tape with-
out loss of padding. Each pad was sealed in a Ziploc bag 
and weighed. All bags were labeled with the subject's 
name and the axilla and date each pad was to be worn. 
A detailed calendar o! the nine-week experimental 
protocol and weekly reminders (Appendix C) were dis-
tributed to each subject to ensure proper compliance. Six 
female and two male volunteers, ages 18-34, followed the 
test guidelines at their own homes and jobs after 
receiving instructions from the investigator. Subjects 
were instructed to observe the area outlined by axillary 
hair. Determining the outline of this region was 
important, because all future sweat collections and 
antiperspirants applications were confined to it. The 
hairy portion of the axilla is the region in which both 
apocrine and eccrine sweating occur. In a survey of panel 
and nonpanel persons, the surface area delineated by 
axillary hair was found to be consistenti.. 
( 
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The calendar was divided into weekly segments. Day 1 
of each week was Sunday; days 2, 3, 4, 5, 6, and ? were Monday, 
Tuesday, Wednesday, Thursday, Friday, and Saturday, 
respectively. On day 4 of the first week, all subjects 
began the axillary hygiene regimen. On day 7, all subjects 
removed axillary hair with Surgex, an effective surgical 
depilatory that removes hair below the skin line (115). 
Removal of a.Xillary hair is essential to provide a clean, 
hairless area to collect sweat (9,23,27,36,55,103). 
Pretest sweat collections began in week 2 on days 4, 
5, and 6, using both axillae as controls. At the start of 
each pretest collection day, the subject washed both axillae 
with Ivory Soap and water, and patted them dry. The 
appropriate pad, cotton side to the body, was taped snugly 
over the clean, dry, delineated axillary area of each 
axilla. Each panelist secured the tape in a manner most 
comfortable for him. Most subjects cut the tape into 1" 
wide strips. The pads were worn throughout a normal day's 
conditions and environment. After a 10-hour collection 
period, the tape was removed, and the pads were returned to 
the designated Ziploc bag and sealed. They were collected 
by the investigator the following morning to be weighed. 
The differe.nce in weight of the tared Ziploc plus dry pad 
and Ziploc plus pad following the 10-hour collection period 
was recorded as the sweat collected. The weight was ex-
pressed in milligrams to the nearest tenth of a milligram. 
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Pretest sweat data are listed in Table 2. 
Pretest sweat ratios were then calculated as 
Perspiration weight from Ri,ht ~illa • Perspiration Ratio 
Perspiration weight from Le t axilla 
and averaged (23). Subjects were then paired by similar 
right to left axillae perspiration ratios (PR). A split 
plot, 4 by 4, Latin Square experimental design (116,117) 
was used to eliminate the possibility that a treated 
heavy- or light-sweating axilla might affect the results. 
One subject of each pair was treated on his heavy-sweating 
axilla, while the other subject was treated on his light-
sweating axilla. For example the PR, 1.636 of subject 
B4D2 and 1.422 of subject B4D1 , indicated both subjects 
sweated more on their right sides. Subject B4n2 •s 
light-sweating or left axilla was chosen randomly as the 
side to be treated for the duration of the test; therefore, 
subject B4D1 •s heavy-sweating or right axilla was treated. 
Their opposite axillae were assigned as the control. At 
no time during the test was any antiperspirant applied to 
the control axillae. 
Treatment sweat collections began during week 3. Test 
antiperspirants designated for the subject for that week 
were supplied in tared sealed containers. The two members 
of a pair applied the same antiperspirant treatment during a 
given week. The four pairs applied different treatments 
during a given week conforming to the Latin Square 
TABLE 2 
PRETEST SWEAT COLLIDTION DATA 
USED FOR BLOCKING 4 BY 4, SPLIT PI.OT, LATIN SQUARE 
Aver~ 
PR• 
1.044 0.787 0.838 
B1D2 115.2 116.2 157.4 231.6 71.1 78.1 
(PR) 0.991 0.680 0.910 o.860 
B2D1 237.2 192.2 56.3 34.2 555.4 262.2 
(PR) 1.234 1.647 2.118 1.666 
B2D2 490.5 293.3 554.0 236.0 230.3 80.1 
(PR) 1.672 2.347 2.875 2.298 
B3D1 1257.4 1202.1 289.3 298.9 865.8 916.2 
(PR) 1.046 0.968 0.945 0.986 
. B3D2 836.0 630.0 468.1 710.2 96.5 119.6 
(PR) 1.327 0.659 0.807 0.931 
B4D1 1742.2 1614.2 1482.7 1255.6 1567.2 781.1 
(PR) 1.079 1.181 2.006 1.422 
B4D2 520.8 296.4 1375.6 970.4 1592.3 918.2 
(PR) 1.757 1.418 1.734 1.636 
• . . R . PersEiration weight ri~ht axilla PR • Perspiration atio • Perspiration weight le t axilla (23) 
46 
( 
( 
) 
47 
design (Table 3). The cream was applied directly to the 
axilla from glassine paper. The stick was applied manually. 
The lotion and hydroalcoholic solution were applied with 
tared cotton swabs. All antiperspirants were applied to the 
designated ~by-4*9inch axillary area. The antiperspirant 
application area was larger than the pad area to assure 
adequate antiperspirant protection in the collection-
si te (Appendix C). 
The axillary hygiene regimen continued in week 3 on 
days 1 and 2. A measured amount of test antiperspirant was 
applied to a clean, dry treated axilla. Tb.is two-day 
period was to accommodate the axilla to the antiperspirant 
(19). No sweat was collected. 
On days 3, 4, and 5, antiperspirant was applied to the 
treated axilla as directed. An elapsed one-minute drying 
time was allowed before taping the tared pads to the axilla. 
A tared pad also was taped snugly to the clean, dry, control 
axilla. The subjects proceeded with their daily routines. 
At the end of the 10-hour collection period, they removed the 
tape and sealed the pads in the designated Ziploc. The pads 
and test antiperspirant containers were collected by the 
investigator to be weighed for daily sweat weights and 
amount of antiperspirant applied. 
A nine-day period, in which no sweat was collected nor 
antiperspirant was applied, was allowed for recovery. The 
axillary hygiene regimen was continued throughout the 
( 
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TABLE 3 
4 BY 4 1 SPLIT PI.OT, LATIN SQUARE DESIGN 
A1 ~ ~ A4 
B~1 A2 A3 A4 A1 
A3 A4 A1 A2 
A4 A1 ~ ~ 
A1 ~ A3 A4 
~ ~ A4 A1 
A3 A4 A1 A2 
A4 A1 ~ A3 
A • Treatments:. 1, stick; 2, cream; 
3, lotion; 4, hyd.roalcoholic base 
B • Subject Pairs, 1, 2, 3, 4 
C • Weeks, 1, 2, 3, 4 
D • Side Treated: 1, heavy-sweating 
side; 2, light-sweating side 
48 
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recovery weeks. Recovery periods, weeks 4, 6, and 8, 
alternated with treatment weeks 5, ?, and 9, using the 
test procedure described above for the duration or the 
experiment. 
3. Statistical treatment of results. Post-test 
sweat collection data were evaluated statistically using 
the geometric mean of treatment results of a 4 by 4, 
split plot, Latin Square design (26,116), illustrated in 
Table 3. The letters D1 and D2 represent the heavy-sweating 
sides and light-sweating sides treated, respectively. The 
columns represent the four treatment weeks, the rows repre-
sent subject pairs, and the blocks indicate the treatments. 
The statistical model describing this treatment design is 
where 
+€ jkmp 
Yjkmp • ln (ratio) • Ln ((mgtreated) - ln (~gcontrol) 
.){ = overall mean 
o<j • treatment j, j•1,2,3,4; ~"'-j • 0 
$ k • subject k, k • 1,2,3,4; i~ k • 0 
'{ m = week m, m • 1,2,3,4; i:. ~ m • 0 
J P • side p, p •1 , 2; ~ S p = 0 
°" S jp • treatment and sides interaction jp.-NID (o,o2) 
/j S kp • subject and sides interaction kp ""NID (o,d-;2) 
( 
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g•mp • weeks and sides interaction mp ,...NID (o,~2 ) 
Ejkmp • error for treatment j, subject k, week m, 
side pA-NID (O, <S 2) 
The AO"V is illustrated in Table 4. 
The sweat ratios were calculated as 
where y • pe~spiration weight (mg) or the treates 8.ide :tand 
x • perspiration weight (mg) of the control side. The 
post-test sweat ratios were transformed to natural 
logarithms to simplify the calculations in the analysis of 
variance table. The F test indicated the absence or presence 
of significant differences in the variables. 
The ratio of treatment axilla to control axilla was 
estimated by 
A 
ln Rj • Aj/8 
the ref ore 
Rj • e(Aj/8) 
A 
where Rj is the post-test treatment ratio mean. 
The antilog or the geometric mean of the data from 
each treatm,ent was calculated and subtracted from unity to 
obtain the percent sweat reduction of each treatment. 
A (1 - Rj) x 100 = percent sweat reduction. 
Confidence intervals of 95 % about the treatment mean, 
,,.--... 
,,.--...._ 
,,.--...._ 
TABLE 4 
ANALYSIS OF VARIANCE FOR 4 BY 4, SPLIT PLOT, LATIN .. SQUARE 
Source of Variation DF SS MS F Test 
Treatments (A) 3 {Aj2/8 - G2/32 SSA/3 MSA"error (A) j 
VI Subject Pairs (B) 3 l.~2/8 - G2/32 SSB/3 MSi1error (A) ~ k 
Weeks (C) 3 {Cm 2/8 - G2/32 
m 
SS0/3 • Ms0/error (A) 
Sides (D) 1 tDP 2/16 - G2 /32 SSif'1 MSif'error (B) 
p 
Subjects x Sides (BD) ' 
2 2 SSBnf 3 MSnif error (B) t~(BDkp) /4 - SSB - SSD - G /32 
kp 
Weeks x Sides 3 2 2 SSci/3 MSclf'error (B) ~~(CD ) /4 - SSC - SSD - G /32 (CD) mp mp 
TABLE 4--Continued 
Source of Variation DF SS MS F Teet 
Treatments x Sides 3 t~(ADjp)2/4 - SSA - SSD - G2/32 SSAJY'3 MSAJY'error (B) (AD) jp 
'" Pooled Residual 12 {{((yjkmp 2 - SSA - S8a - SSC -I\) jkmp 
~ 2 
SSD - SSAD - SSan - SScn - G /32 
SSAB' 6 ~i(BC~/2 - SSA - S8a - ss0 - G2/32 error (A) km 
SSABD' 6 Pooled Residual - SSAB' error (B) 
31 2 2 TOTAL ~l~ty'jkmp - G /32 jkmp 
( 
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A 
Rj' were estimated by 
( •j/S) ! t ~ f error (A) 
A 6~;05 v 8 
The upper and lower confidence limits were expressed in terms 
of percent sweat reduction by 
and 
(1 - e1 ) x 100 
where eu and e1 a.re the antilogs of the upper and lower 
confidence limits, respectively. 
Having shown significant treatment differences with 
the F test, the Least Significant Difference (LSD) test 
was performed to make individual comparisons of differences 
between pairs of treatments. 
-
where xi' xj • treatment means. 
2 (error (A)) 
8 
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IV. DISCUSSION AND RESULTS 
The tests were organized so that there was a two-week 
abstinence from antiperspirant use before the treatment 
sweat collections began. Subjects abstained from anti-
perspirant u~e for one week before the three pretest sweat 
collection readings were made. Tb.ere was a one-week re-
covery period of no antiperspirant use between treatments. 
Abstinence from antiperspirants ensured no carry-over effect 
from previous antiperspirant use. All eight subjects 
collected sweat for three collection days per treatment. 
All subjects were tested on all four treatments. 
The F test (Table 5) indicates differences in 
treatment effects, sides by subjects effects, and weeks 
by sides effects. No significant differences were found 
in subjects, weeks, sides or treatments by sides. 
It is of particular interest that the sides' (D) 
F value was extremely low. The pretest blocking pro-
cedure was instituted to account for the light- or heavy-
sweating side treated, yet the results indicated that the 
side which was treated could have been randomly selected 
without regard to pretest sweat ratios. This is in 
agreement with Wooding and Finklestein's (26) decision to 
eliminate pretest sweat ratios in evaluating antiperspirant 
efficacy. This result is further substantiated by the 
~ 
( 
TABLE 5 
ANOVA OF POST-TEST DATA 
Source of Variations DF SS MS F Value• 
Treatments (A) 3 1.411 0.470 5.311 
Subject Pairs (B) 3 0.659 0.220 2.486 
Weeks (C) 3 0.079 0.026 0.294 
Sides (D) 1 0.004 0.004 0.125 
( -::Subjects _ _x~Sid.es 3 
. .!BD) 1.002 0.334 10.438 
Weeks x Sides 3 0.616 0.205 6.406 (CD) 
Treatments x Sides 3 0.145 0.048 1.500 (AD) 
Pooled Residual 12 0.721 0.060 
SSAB' 6 0.531 0.0885 (error (A)) 
SSABD' 6 0.190 0.0320 (error (B)) 
TOTAL 31 4.637 
•where F3 , 6 ,. 05 • 4.76 
.. 
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insignificant F value of subject pairs (B). Subjects were 
paired by similar pretest treatment ratios. One subject 
was treated on his heavy-sweating side, while his paired 
opposite was treated on his light-sweating side. Supject 
pair 3 had pretest sweat ratios very close to unity 
(Table 2) in which case it was an arbitrary decision to 
call a side light- or heavy-sweating. Treatment by sides 
effects (AD) .. indicates that the side to which the treatment 
is applied is not significant. 
However, the F value indicates a strong subjects by 
sides (BD) effect. Figure 3 gives an indication of why 
this difference occurred. By plotting the light side to 
heavy side pretest sweat ratio average of each subject pair 1 
versus the sum of the treatment ratios' natural logarithms 
of each subject by side (BD), the cause of the interaction 
is readily observable. All subject pairs exhibited 
similar sides by subjects effects, except subject pair 3. 
This interaction is of particular interest because they had 
pretest sweat ratios close to unity. Their daily pretest 
sweat ratios showed extreme day-to-day variations, but 
averaged close to unity. Steed (9) also observed marked 
variations in subjects with pretest ratios close to unity. 
Otherwise, .the other three subject pairs had no difference 
in this effect. 
As expected, there was no significant difference in 
treatment weeks effects (C). During each of the four 
( 
1.0 
o.o 
-1.0 
-2.0 
L/H 0.5 
B 2 
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x Heavy-sweating side treated 
• Light-sweating side treated 
• 
0.6 0.7 0.8 0.9 
4 1 
1.0 
Figure 3. The pretest sweat ratios of light-
sweating side to heavy-sweating side (L/H)· 
of Subject Pairs (B) versus Subjects by 
Sides (!\(BDkp)) illustrates the Subjects 
by Sides interaction occurs in Subject Pair 3. 
( 
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treatment weeks, all four treatments were tested, with each 
subject pair testing a different treatment in a given week, 
and no pair testing the same treatment in the same week. 
There was no major change in the sum o! the ratio's natural 
logarithms for each treatment week (~Cm)' despite the fact 
that during the first three treatment weeks the average 
environmental temperature was in the low 60sfF .: and the 
average relative humidity was 40}6, while in treatment week 
4, the average temperature was in the high ?Os~F ' and the 
average relative humidity was ?Cf), (118). Most subjects 
were wearing lightweight sweaters during this period and 
working indoors. However, weeks by sides (CD) exhibited 
a significant difference. Figure 4. plots the treatment 
week versus the sum of each treatment week by side 
(~tCDmp). Heavy- versus light-side treatment shows a 
major change during week 3. Since this does not appear 
to be due to environmental factors, it may well have been 
caused by emotional factors. Treatment week ;, May ?, 
occurred during the last week o! classes or examination 
periods for the subjects, who were all in academic 
surroundings. There was a great deal of pressure on the 
subjects to finish course work and write exams. Emotional 
sweating h~s been suggested as a cause of erratic sweat 
ratios and rates (57,58). However, it did not affect the 
antiperspirants' effectiveness. All subjects participated 
in muscular exercise, such as tennis, jogging, or dancing, 
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1.0 
x • Heavy-sweating side treade 
• • Light-sweating side treate 
o.o 
• 
-1.0 
x 
-2.0 
c 1 2 
Week of 4-9-78 4-23-78 
Average RH (%) 40 30 
Average T (°F) 50s 60s 
3 
5-7-78 
50 
60s 
4 
5-21-78 
70 
70s 
Figure 4. The effect of Weeks (C) versus Weeks by 
Sides (it(CDmp)) indicates an interaction during 
Week 3, a possible result of emotional stress 
on sweating. The average relative humidity (RH) 
and temperature (T) did not markedly affect 
--sweating ratios. 
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at various ti.mes. This activity was noticeable in daily 
sweat collection weights, but not in overall sweat ratios • 
.Antiperspirant effectiveness was maintained during exercise. 
A significant difference in treatments was caused by 
the stick antiperspirant. The natural logarithms of the 
treatment means (ln Rj) in Table 6 showed a marked 
difference in treatment 1's mean compared to the other 
three treatment means. This is verified by the LSD test. 
However, no significant difference was found among treat-
ments 2, 3, and 4. 
Percent sweat reduction results in decreasing order 
of antiperspirant effectiveness response are treatments 3 
(lotion, 38.CJ'h), 4 (hydroalcoholic solution, 32.4%), 
2 (cream, 31.8%), and 1 (stick, ~6.2°fe). Percent sweat 
reductions and their confidence intervals are shown in 
Table 6. The wide confidence intervals, a result of a 
low degree of freedom and high standard deviation 
(error (A)), are not uncommon in antiperspirant efficacy 
testing at normal temperatures (9,57). However, percent 
sweat reduction results of the treatments containing 
Chlorhydrol, 50% w/w solution, agreed with previous studies 
(4,9,19,96,108). 'lb.e previous studies showed sweat re-
duction averaged 30-4ry;~ , regardless of concentrations of 
antiperspirant agent applied. Table 6 lists the average 
dose of active antiperspirant agent applied. It is curious 
to note that the lotion with the lowest dose applied obtained 
,,,.--..._ 
"""""' 
TABLE 6 
ANTIPERSPIRANT TREATMENT EFFICACY AND DOSAGE 
Percent Confidence Average Average Dose 
Sweat Intervals, Treatment Active Agent 
Treatment a in R b Reduction 95% Applied Applied (%) (%) (mg) (mg) 
(}) 
j 
....l. 
A1 0.060 -6.2 -37.3 to 17.9 143.04 69.16 
~ -0~382 31.8 11.8 to 47.2 379.96 75.99 
A3 -0.478 38.0 19.8 to 52.0 172.76 34.55 
A4 -0.391 32.4 12.5 to 47.7 263.52 52.70 
aA1 , stick; ~' cream; A3 , lotion; A4 , hydroalcoholic solution. 
bRatio of treated axilla to control axilla estimated by ln Rj • Aj/8. 
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the best antiperspirant efficacy results, while the stick 
with a high dose of active ingredient applied increased 
sweating on the treated side. Subjects generally applied 
the same amount of a given antiperspirant during the 
treatment week. Individual subjects tended also to be 
consistent in the application of a small or large amount 
of antiperspirant throughout the test. Since subjects 
applied the treatments themselves, this may be a result of 
personal preference for commercial antiperspirant quantities 
used routinely before engaging in this experiment. 
Personal acceptance of a product frequently plays an 
important role in the effectiveness of a product (11,64,96). 
The lotion was considered the most cosmetically acceptable 
and elegant dose form by all subjects, while the stick form 
brought many complaints. The subjects used commercial 
aerosols or roll-on antiperspirant/deodorant products 
prior to testing. None of the subjects had ever used a 
stick or cream-based antiperspirant before. This may also 
have influenced their acceptance or rejection of the 
vehicles. 
A small scale test was conducted by one subject using 
only the stick vehicle minus the active ingredient. This 
subject followed the same protocol used during the test 
weeks. The average sweat ratio was close to unity. Daily 
ratios also were close to unity. Since the subject's 
heavy-sweating side was treated and a decrease in sweat on 
( 
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the treated side was observed, the base was ruled out as a 
properspirant. Of course, ratios close to unity, as noted 
previously in subject pair ;, produced erratic results. 
Increased sweat ratios with the stick formulation may have 
been caused by the antiperspirant agent being suspended in 
the vehicle coupled with difficulty in application. 
The antiperspirant agent was in suspension in the stick 
formula, rather than in solution as in the other three 
treatments (95-97). The activity of MicroDry, Ultrafine 
was dependent on the dispersing agent, Procetyl AWS. The 
activity of topically applied drugs is often influenced by 
their release rates of drugs from the carrier vehicle (1-10, 
91). 
The incorporation of MicroDry, Ultrafine into the 
stick base resulted in a hardening, caused by the 
suspension and the dry, impalpable powder in the base, so 
that the product was heavier and more difficult to apply 
than the vehicle alone. 
Day-to-day sweat ratios vary, although the heavy-
sweating side usually remains the same. It is of 
particular interest to note that, when the same amount of 
active ingredient was applied to a given subject during a 
given treatment week, the sweat ratios still varied from 
day-to-day, but did not affect overall antiperspirant 
efficacy. This daily fluctuation in sweat ratios was the 
reason for considering all collection data, regardless 
( 
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of a day of light or heavy sweating. Sweat collection data 
of all participants were used whether they sweat profusely 
or sparingly. These data reflect a normal population 
that makes use of antiperspirants in the daily environment. 
The effect of dominant-handedness on sweat ratios could 
not be assessed conclusively. Of eight subjects, four 
sweat more on the right axilla, but one of these four was 
left-handed. · Two subjects had sweat ratios close to unity. 
Their heavy-sweating sides were on the left. Both these 
subjects were right-handed. Of the two subjects with a 
heavier sweating left axilla, one was right-handed and the 
other was left-handed. 
The males, who removed their axillary hair for the 
first time, noted a marked decrease in: axillary odor (36,3S, 
54,55) and developed an immediate dermatitis-like reaction 
following the first application of Surgex. Tb.is reaction 
disappeared within 24 hours without medical treatment. It 
did not recur in subsequent applications. The females did 
not complain of irritation from Surgex. The daily sweat 
volume of the majority of females was greater than that of 
the two male subjects. 
Aside from discomforture experienced with the stick 
form, no co~plaints of irritation from antiperspirant test 
products were recorded. The incorporation of allantoin 
complex in combination with aluminum chlorhydrate was 
apparently beneficial in reducing antiperspirant irritant 
( 
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potential and enhancing cosmetic qualities of the dose form. 
However, the use of the cloth hypoallergenic tape became 
uncomfortable by the third collection day. This did not 
apJPSar to affect sweat weights or ratios. Exercise and 
emotional stress had the greatest effect on sweat weights. 
Future Studies 
1. Antiperspirant efficacy could be tested in 
individuals who exhibit sweat ratios close to unity. The 
same test could be conducted on subject pair 3 with re-
versed sides treated to see if the same interaction would 
occur and how unity ratios affect sweating. 
2. Studies could be designed to test varying 
concentrations of the same agents in the same vehicle and 
in different vehicles. 
3. A detailed study could be conducted of anti-
perspirant release rates from various vehicles, especially 
a solution versus a suspension. Further studies are needed 
of the stick vehicle only compared to the stick anti-
perspirant and how individual vehicular components affect 
the active ingredient~s release rate. 
4. This study could be repeated exactly as presented 
here, using the same subjects and having them each apply 
identical amounts of active ingredient to the axilla, then 
comparing results in ordinary and controlled environments. 
( 
( 
V. CONCLUSIONS 
1. It is concluded that vehicle does not affect 
antiperspirant efficacy. 
2. However, release rate of the active ingredient from 
the vehicle plays an important role in antiperspirant 
efficacy, as observed with aluminum chlorhydrate in solution 
in the cream base, aqueous lotion, and hydroalcoholic base 
versus aluminum chlorhydrate in suspension in the solid 
stick. 
3. Antiperspirant treatment response in terms of 
percent sweat reduction (in decreasing order of effectiveness) 
was: lotion, 38.0'%; hydroalcoholic solution, 32.4%; cream, 
31.SC/o, and stick, -6.2'/o. The gravimetric testing pro-
cedure conducted during a normal work day in each subject's 
normal work environment produced percent sweat reduction 
results well within the acceptable antiperspirant 
efficiency ranges. 
4. The 4 by 4, split plot, Latin Square experimental 
design was statistically satisfactory. Statistical analysis 
indicated that the side treated may be selected randomly 
without compromising the results. 
5. Sweat weights may be affected by temperature, 
muscular exercise, or emotional stress. However, these 
factors did not affect antiperspirant efficiency. 
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VI. APPENDICES 
APPENDIX A 
Several preliminary formulations were tested and 
compared for physical and chemical compatibility, 
stability, and cosmetic elegance and acceptability. 
Physical and chemical compatibility results led to the 
selection of aluminum chlorhydrate over modified aluminum 
chlorhydroxy allantoinate as the active agent. Aluminum 
chlorhydroxy allantoinate in concentrations of 0.25% was 
added to formulations containing aluminum chlorhydrate for 
its therapeutic and cosmetic properties. The formulations 
listed below are examples of preliminary formulations tested. 
Several additional preparations based on the listed 
formulas were formulated by varying the concentrations of 
cert ~in component ingredients to aid in the selection of 
the test antiperspirant products. 
The following product is an example of a basic 
oil-in-water emulsion (90). It was a well~textured cream; 
however, it was stiff and dry on application. 
%, weight 
A. Stearic Acid ••••••••••••••••••••••••••••••• 15.0 
Arlacel 60 •••••••••••••••••••••••••••••••••• 5.0 
Tween 60 SD ••••••••••••••••••••••••••••••••• 5.0 
B. Distilled water •••••••••••••••••••••••••••• 55.0 
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o. Aluminum chlorhydroxy 
• allantoinate modified •••••••••••••••••••• 20.0 
100.0 
Preparation: Heat A and B separately to 85°0. Add B 
to A with constant agitation until cooled to 45°0. Add 
C. Stir until a smooth mixture is formed. 
This product (90) was a smooth, homogenous, fluffy, 
cosmetically appealing cream. It deposited a fine, 
white, quick-drying film upon application. 
A. 
%, weight 
Sodium lauryl sulfate •••••••••••••••••••••• 2.00 
Distilled water ••••••••••••••••••••••••••• 15.00 
B. Titanium dioxide ••••••••••••••••••••••••••• 0.25 
O. Aluminum chlorhydroxy 
allantoinate modified ••••••••••••••••••• 15.00 
Distilled water ••••••••••••••••••••••••••• 42.75 
D. Spermaceti ••••••••••••••••••••••••••••••••• 3.00 
Glyceryl monostearate ••••••••••••••••••••• 16.00 
Myri 52••••••••••••••••••••••••••••••••••••6.00 
100.00 
Preparation: Stir A until dissolved. Suspend B in 
A, warm to 70°0. Stir 0. until dissolved and warm to 
70°0. Heat D slowly with constant agitation to 65°0. 
Run D into mixture AB while stirring. Slowly add 0 at 
60°0. Stir constantly to 40°0. 
This stiff, cosmetically undersirable cream 
contained 
%, weight 
A. Amerchol L-101 ••••••••••••••••••••••••••••• 3.00 
Modulan •••••••••••••••••••••••••••••••••••• 2.00 
Spermaceti ••••••••••••••••••••••••••••••••• 4.00 
G-2162•••••••••••••••••••••••••••••••••••••2.00 
Myrj 5.2••••••••••••••••••••••••••••••••••••2.00 
Glyceryl monostearate ••••••••••••••••••••• 17.00 
B. Propylene glycol ••••••••••••••••••••••••••• 3.00 
Distilled water ••••••••••••••••••••••••••• 27.75 
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C. Chlorhydrol, 50'fe w/w solution ••••••••••••• 38.00 
Aluminum chlorhydroxy allantoinate ••••••••• 0.25 
Titanium dioxide ••••••••••••••••••••••••••• 1.00 
100.00 
Preparation: Heat A and B separately with constant 
stirring to 85°C. Add B to A slowly, stirring 
constantly to 40°C. Add C to mixture and stir to 35°C. 
A cosmetically elegant cream that was easy to apply 
was formulated (94). However, the desirability of limiting 
the number of component ingredients in the test procedure 
eliminated this formula. 
%, weight 
A. Veegum.•••••••••••••••••••••••••••••••••••••2.00 
Distilled water ••••••••••••••••••••••••••• 41.75 
B. Amerchol L-101•••••••••••••••••••••••••••••5.00 
Solulan 98•••••••••••••••••••••••••••••••••1.00 
Ce~yl alcohol •••••••••••••••••••••••••••••• 1.00 
Arlacel 165••••••••••••••••••••••••••••••••7.00 
C. Chlorhydrol, 50 % w/w solution •••••••••••• 40.00 
Aluminum chlorhydroxy allantoinate ••••••••• 0.25 
Glycine •••••••••••••••••••••••••••••••••••• 2.00 
100.00 
Preparation: Add Veegum to water slowly, agitating until 
smooth. Heat to 80°C. Heat B to 70°C. Add B and A 
stirring constantly. Cool to 35°C. Mix C at room 
temperature until a clear solution is formed. Add C to 
mixture AB. Continue stirring until a smooth, 
homogeneous cream is formed. 
An extremely viscous oil-in-water lotion emulsion 
was prepared (94). The consistency was suitable for 
roll-on application; however, a simple aqueous lotion 
was preferred as a test vehicle. 
%, weight 
A. Amerchol L-101 ••••••••••••••••••••••••••••• 5.00 
Solutan 98 ••••••.••.•......••...•••.••.•••• 2.00 
Cetyl alcohol •••••••••••••••••••••••••••••• 1.00 
Arlacel 165 ••••••••••••••••••••••••••••••• ~4.00 
Glycerine •••••••••••••••••••••••••••••••••• 2.00 
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B. Veegum•••••••••••••••••••••••••••••••••••••o.50 
Distilled water ••••••••••••••••••••••••••• 49.25 
c. Chlorhydrol, 5CYJ~ w/w solution ••••••••••••• 36.00 
Aluminum chlorhydroxy allantoinate ••••••••• 0.25 
100.00 
Preparation: Disperse Veegum thoroughly in ·-water at ·Doam 
temperature. Heat to 90°C and hold at this temperature 
vhile stirring for one hour. Heat A to 80°C. Add B to 
A slowly with constant stirring. Stir to 40°C. Add c. 
Continue stirring to 35°C. 
The following two formulas (99) are examples of the 
solubility difficulties encountered in preparing an 
alcohol-based antiperspirant with the alcohol soluble 
form of modified aluminum chlorhydroxy allantoinate. 
%, weight 
A. Alcohol soluble aluminum chlorhydroxy 
allantoinate modified ••••••••••••••••••• 20.0 
Stearic acid •••••••••••••••••••••••••••••.•• 2.0 
Ethanol, 959b •••••••••••••••••••••••••••••• 76. 0 
B. Arlamol E •••••••••••••••••••••••••••••••••• 2.0 
100.0 
Preparation: Dissolve A at room temperature. Add B, 
stirring until a clear solution is formed. 
%, weight 
A. Ethanol, 95% •••••••••••••••••••••••••••••• 70.0 
Arlamol E •••••••••••••••••••••••••••••••••• 5.0 
B. Alcohol soluble aluminum chlorhydroxy 
allantoinate modified ••••••••••••••••••• 20.0 
~istilled water••••••••••••••••••••••••••••5.0 
Preparation: Stir A at room temperature until a clear 
solution is formed. Slowly add B and stir until clear. 
This quick-drying, nontacky solution was formulated 
employing a concentration of Rehydrol equivalent to doses 
af aluminum chlorhydrate in the test products (99). 
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%, weight 
A. Rehydrol••••••••••••••••••••••••••••••••••26.70 
Ethanol, 95%••••••••••••••••••••••••••••••46.30 
B. Distilled water ••••••••••••••••••••••••••• 24.75 
Alcohol soluble aluminum chlorhydroxy 
allantoinate ••••••••••••••••••••••••••••• 0.25 
C. Arlamol E •••••••••••••••••••••••••••••••••• 2.00 
Preparation: Dissolve separately A and B. 
A. Stir until a clear solution is formed. 
Stir until clear. 
100.00 
Add C to 
Add B. 
The acidic aluminum salts are not suitable for use in 
a sodium stearate-based stick. Bodium aluminum chlorhydroxy 
lactate, forms a cosmetically acceptable, yet ineffective 
soap-based antiperspirant stick. The neutral gelling 
agent, Crodesta A 10, produces a stick of suitable 
consistency. The addition of silicone fluid reduces 
tackiness and enhances stick slip and structure. 
However, the following formula (97) crumbled upon 
appl ication. 
%, weight 
A. Crodesta A 10 ••••••••••••••••••••••••••••• 28.00 
Procetyl AWS •••••••••••••••••••••••••••••• 10.00 
B. Rehydrol •••••••••••••••••••••••••••••••••.• 20.00 
Alcohol soluble aluminum chlorhydroxy 
allantoinate ••••••••••••••••••••••••••••• 0.25 
c. Silicone Fluid 200, 1000cps ••••••••••••••• 41.75 
Preparation: Heat A to 65°C. Add B. 
Wliform. Add C. Stir until smooth. 
suppository molds to cool. 
100.00 
Stir Wltil 
Pour into 2-gram 
The following water-in-oil emulsion stick (97) 
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was cosmetically unacceptable. The stick was dry and tacky 
upon application. The excessive number of component 
ingredients, and the emulsion base, were additional 
reasons to eliminate~ this product. 
%, weight 
A. Veegum ••••••••••••••••••••••••••••••••••••• 1.00 
Distilled water ••••••••••••••••••••••••••• 29.75 
MicroDry, Ultrafine ••••••••••••••••••••••• 20.00 
Aluminum chlorhydroxy allantoinate ••••••••• 0.25 
B. Super Hartolan•••••••••••••••••••••••••••••2.00 
Amerchol . L-101 •••••••••••••••••••••••••••• 10.00 
Amerchol CAB ••••••••••••••••••••••••••••••• 4.00 
Stearic Acid •••••••••••••••••••••••••••••• 16.00 
Paraffin ••••••••••••••••••••••••••••••••••• 3.00 
Silicone Fluid 200, 1000 cps ••••••••••••••• 3.00 
Propylene glycol •••••••••••••••••••••••••• 10.00 
Arlacel 186••••••••••••••••••••••••••••••••1.00 
100.00 
Preparation: Disperse the Veegum in water. Add 
the MicroDry and allantoin complex. Heat A with 
constant stirring to 85°C. Heat B with constant 
stirring to 85°C. Add A to B and blend until smooth. 
Pour into 2-gram suppository molds to cool. 
The stick antiperspirant formula was adapted from 
a lipstick base. The stick's consistency was cosmetically 
undesirable.for antiperspirant application .(92). 
%, weight 
A. Ozokerite •••••••••••••••••••••••••••••••••• 6.00 
Carnauba wax, yellow #1 •••••••••••••••••••• 4.00 
Candelilla wax•••••••••••••••••••••••••••••8.00 
Propylene glycol •••••••••••••••••••••••••• 51.35 
Tenex BHT •••••••••••••••••••••••••••••••••• 0.10 
B. Crodamul IPM •••••••••••••••••••••••••••••• 10.30 
c. MicroDry, Ultrafine ••••••••••••••••••••••• 20.00 
Aluminum chlorhydroxy allantoinate ••••••••• 0.25 
100.00 
Preparation: Heat A to 90°C with constant stirring. 
stirring until smooth. Add C, stirring until smooth. 
into 2-gram suppository molds to cool. 
Add B, 
Pour 
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APPENDIX B 
Experimental Protocol 
The Effect of Vehicle on Antiperspirant Efficacy 
College of Pharmacy, University of Rhode Island, 1978 
Investigators: 
M. H. Smith, B.S. 
Graduate Student 
J. M. Lausier, Ph.D. 
Associate Professor, Department of Pharmacy 
G. E. Osborne, Ph.D. 
Professor, Department of Pharmacy 
C. T. Rhodes, Ph.D. 
Chairman and Professor, Department of Pharmacy 
C. I. Sn).ith, Ph.D. 
Chairman and Professor, Department of Medicinal Chemistry 
Objectives: This study is concerned with how 
vehicular excipients in an antiperspirant formulation affect 
the efficacy of the product. Using a single, proven antiper-
spirant entity in different vehicles, we shall examine the 
effect of those vehicles on the efficacy of typical cosmetic 
products. A roll-on lotion, a cream base, a solid stick, 
and an alcohol base such as one used in the manual pump 
spray will be formulated and evaluated gravimetrically for 
the influence of vehicle on antiperspirant efficiency. 
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Preliminary Screening of Subjects: Subjects con-
sidered for this study will be heal tbT.",'pers.ons··nth· ·no bro·ken 
or irritated axillary skin and no sensitivities to Aluminum 
Chlorhydrate, Aluminum Chlorhydro:xy Allantoinate, or 
thioglycollates. Subjects will undergo sample patch tests 
several days prior to testing to check for sensitivities, 
toxicity, and irritation that may result from the anti-
perspirant products or the hair-remover cream. Any medical 
or cosmetic abnormality which the investigators believe may 
be likely to complicate the study will exclude the subject. 
All subjects will be interviewed carefully and 
pertinent medical, especially dermatological, information 
will be gathered. Investigators will explain the informed 
consent form to all participants. All participants will 
have read the informed consent form before they will be 
allowed to sign it. Participants will be able to question 
the investigators. Any subjects may withdraw from the study 
at any time during the investigation. 
Participants will be required to abstain from non-test 
antiperspirant/deodorant use during the test period, remove 
axillary hair with a surgical depilatory at designated 
intervals during the test period, and wash the axillary area 
with Ivory Soap and water only. 
The test will be conducted during a normal work day 
for 10 hours in the subject's normal work environment. 
Results will be evaluated statistically using a gravimetric 
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technique. 
~ach subject will be supplied with Surgex, a 
hair-remover cream, Ivory Soap, tared adsorbent pads in 
sealed plastic bags, and antiperspirant products to be 
tested. 
The subject will be requested to maintain normal 
bathing habits throughout the test period with the ex-
ception of the axillary hygiene regimen. The axillary 
hygiene regimen consists of washing the axillary region 
with Ivory Soap and water only, patting the area dry, and 
removing axillary hair at designated intervals during the 
test period. Only products supplied by the investigators 
may be used under the axillary region. 
Sweat will be collected on tared absorbent pads 
taped snugly to the axillae with hypoallergenic tape. A 
treated and control axilla (e.g., right axilla treated with 
left axilla as control) will be assigned to each subject and 
the treated and control axillae will remain the same through-
out the test period. At no time should any antiperspirant 
be applied to the control axilla during the test period. 
Experimental Prodedure Calendar: The calendar is 
divided into weekly segments. Day 1 of each week is Sunday, 
day 2 is Monday ••• day 7 is Saturday. 
Week 1: Day 4 (Wednesday) begin axillary hygiene 
regimen as described above. Discontinue the use of present 
antiperspirant. Day 5-6-7 continue axillary hygiene regimen. 
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Day ? use Surgex on both axillae as directed. 
Week 2: Day 1 continue axillary hygiene regimen. 
Day 2-3 continue axillary hygiene regimen. Day 4-5-6 pretest 
sweat collection period begins using both axillae as controls. 
Tape the tared adsorbent pad snugly to a clean, dry axilla. 
Proceed with your normal daily work or routine. At the end 
of the allotted time period, remove the tape and place the 
tared adsorbent pad in the designated plastic bag and seal. 
These materials will be collected by the investigators. 
Day 7 continue axillary hygiene regimen, but no sweat will 
be collected. Use Surgex on both axillae as directed. 
Week 3: Day 1-2 continue axillary hygiene regimen. 
Apply test antiperspirant to premeasured area under clean, 
dry treated axilla. 0ontrol axilla should be washed with 
Ivory Soap and water only and patted dry. This two-day 
period is to accommodate the axillae to the antiperspirant. 
No sweat will be collected. Day 3-4-5 apply test anti-
perspirant to premeasured area under clean, dry treated 
axilla. Wait one minute for antiperspirant to dry, then 
tape tared a(i.sorbent pad snugly to the axilla. Tape a 
tared aasorbent pad snugly to the clean, dry control axilla. 
Proceed with daily routine. At the end of the allotted 
time period., remove the tape, and store the pads in the 
designated plastic bags and seal. These materials will be 
collected by the investigators. Day 6-7 proceed as in 
week 3, day 1-2. 
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Week 4: Day 7 remove axillary hair with Surgex as 
directed on package insert. Continue axillary hygiene 
regimen. Day 1-7 is a recovery period. Continue with 
axillary hygiene regimen. No sweat will be collected and no 
test or non-test antiperspirants will be used. 
Week 5: Testing of a second antiperspirant begins. 
Proceed as in week 3. 
Week 6: Recovery period. Proceed as in week 4. Apply 
Surgex on day 7. 
Week 7: Testing of a third antiperspirant begins. 
Proceed as in week 3. 
Week 8:· Recovery period Proceed as in week 4. 
Apply Surgex on day 7. 
Week 9: Testing of a fourth antiperspirant begins. 
Proceed as in week 3. Day 7 is end of testing. 
Note: Effective antiperspirant concentrations of 
Aluminum Chlorhydrate range from 20 to 40 percent in the 
vehicles being tested. No adverse effects have been reported 
at these concentrations. 
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Informed Consent Form 
The Effect of Vehicle on .Antiperspirant Efficacy 
College of Pharmacy, University of Rhode Island, 1978 
Investigators: 
M. H. Smith, B.S. 
Graduate Student 
J. M. Lausier, Ph.D. 
Associate Professor, Department of Pharmacy 
G. E. Osborne, Ph.D. 
Professor, Department of Pharmacy 
c. T. Rhodes, Ph.D. 
Chairman and Professor, Department of Pharmacy 
C. I. Smith, Ph.D. 
Chairman and Professor, Department of 11edicinal Chemistry 
Aluminum Chlorhydrate is an effective antiperspirant 
agent used to reduce perspiration. It is supplied normally 
to the consumer as the active ingredient in antiperspirant 
roll-on lotions, creams, solid sticks, aerosols, and manual 
pump sprays, which are applied topically to the axillae as 
needed to reduce perspiration and body odor. 
The objective of this research project is to formulate 
typical antiperspirant products in cosmetically acceptable 
finished forms and evaluate gravimetrically the influence 
of the vehicles on antiperspirant efficiency. 
Should you volunteer to participate in the project, 
you will be required to abstain from non-test antiperspirant/ 
deodorant use during the test period, remove axillary hair 
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at designated intervals during the test period, and wash the 
axillary area with Ivory Soap and water only. 
You must have no broken axillary skin or sensitivities 
to Aluminum Chlorhydrate, Aluminum Chlorhydroxy- Allantoinate, 
or thioglycollates. All necessary test materials will be 
prepared and supplied by the investigators. The anti-
perspirant products will contain effective levels of 
Aluminum Chlorhydrate in a roll-on lotion, a cream base, 
a solid stick, and an alcohol base ( such as one used 
in the manual pump sprcS."f1~ The safety and efficacy of 
Aluminum Chlorhydrate as an antiperspirant are well 
established; it causes no damage to fabric. To 
minimize or eliminate sensitivity reactions and irritation 
to the axillary region, concentrations of 0.25% Aluminum 
Chlorhydroxy Allantoinate will be incorporated into the 
antiperspirant products. Aluminum Chlorhydroxy 
Allantoinate combines the astringent bacteriostatic properties 
of Aluminum Chlorhydrate and the sustained healing activity 
of allantoins. It has proven to be non-toxic, non-irri-
tating, and even healing to irritated axillae. 
To eliminate the irritation and broken skin 
associated with shaving of axillary hair, a safe and 
effective surgical depilatory, Surgex, will be used to 
remove axillary hair. It should not be applied to the 
axillae within 48 hours of shaving. 
Local skin irritation or sensitization at the site of 
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application is one possible effect of the depilatory and/or 
antiperspirant products. As a volunteer for this project, 
you may withdraw from it at any time during the investi-
gation. You will not be identified in any publication 
resulting from this work. 
I, 
~~~~~--~~----------
, after reading and 
understanding the above and having the opportunity to ask 
questions regarding the above project now give my informed 
consent for participation in the antiperspirant vehicle 
evaluation project, University of Rhode 1sland. 
Witness Date of Birth ------~---------------- -----------------
APPENDIX C 
This appendix contains a sample nine-week 
experimental protocol calendar and weekly reminders 
distributed to the volunteers during this study. All the 
volunteers followed the test guidelines at their own 
homes and jobs after receiving instructions from the 
investigator. Distribution of these materials was 
well-accepted by the subjects as an aid in complying 
with the experimental protocol. 
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Day 
Week 
1 
2 
PRETEST 
3 
AP T #1 
1 
SUNDAY 
Al?_ril 2 
AP T #1 
--
ANTIPERSPIRANT EXPERIMENTAL PROTOCOL 
CALENDAR 
2 3 4 5 
MONDAY TUESDAY WEDNESDAY THURSDAY 
BEGIN 
March~ March _2_0 
Swea ~ Collecti pn Pads 
Al?_ril _2_ Al?_ril 4 1\I>_ri 1 _2_ 1\I>_ril 6 
Swea t Collecti pn Pads 
T/C T/C T/C 
AP T #1 AP T #1 AP T #1 AP T #1 
AJ?_ril ~ Al?_l'il 10 A~ril 11 A.E_ril 12 A~ril 13 
~--
6 7 
FRIDAY SATURDAY 
SURGEX 
March _31 J\pril 1 
SURGEX 
AJ;>_ril 2 Al?_ril 8 
A_p_ril 14 A_E_ril 15 
CX> 
\)I 
Day 
Week 
4 
Recovery 
5 
AP T #2 
6 
Recovery 
1 2 
SUNDAY MONDAY 
I I 
I AP T #2 I AP T #2 
,......_ 
~-
CALENDAR--continued 
3 4 
oorfu,DAY I 6 I SArfrRDAY TUESDAY WEDNESDAY FRIDAY 
I I SURGEX 
I I I I 
A ril 21 A ril 22 
Swe Collect· n Pads 
SURGEX 
Ma:v 2 4 M 6 
~ 
,,--. 
Day 
Week 
7 
AP T #3 
8 
Recovery 
9 
APT #4 
,--.... 
CALENDAR~continued 
1 
SUNDAY 
2 
MONDAY 3 I 4 I 5 I 6 I 7 TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY 
swelt co11ectirn Pads 
T/C T/C TIC 
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IMPORTANT: Continue axillary hygiene regimen with Ivory Soap throughout the test 
period. Apply collection pads to a clean, dry axilla. 
AP T #, antiperspirant treatment number 
T/C, apply antiperspirant treatment to TREATED AXILLA, apply pads to both axillae 
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Reminder Antiperspirant Volunteers 
Week 2 
On Saturday, April 1, 1978, use Surgex under both 
axillae. 
On Sunday, April 2, 1978, and Monday, April 3, 1978, 
continue with Ivory soap regimen. 
On Tuesday, April 4, 1978, collect sweat with pad 
provided for . 10 hours. Be sure to apply the pad marked 
Right Axilla to the RIGHT underarm area and the pad marked 
Left Axilla to the LEFT underarm area. Dermicel Cloth 
hypoallergenic tape is provided. Place the soft cotton 
side of the pad against the skin. Place the tape to the 
plastic covered side. Tape pad suugly to appropriate 
axilla. At the end of the 10-hour period, place the pad 
under the RIGHT axilla in the bag marked Right Axilla. 
Be sure to squeeze all the air out of the bag before 
sealing. Seal the bag securely. Do the same with the Left 
Axilla pad. Bring the 2 marked bags in the following 
morning. 
On Wednesday, April 5, 1978, collect sweat for 10 
hours with pads provided. Apply pads as indicated in 
Tuesday's procedure. 
On Thursday, April 6, 1978, collect sweat for 10 
hours. Apply pads as indicated in Tuesday's procedure. 
On Friday, April 7, 1978, continue Ivory Soap 
regimen. 
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On Saturday, April 8, 19?8, use Surgex under both 
axillae. 
NOTE: The Ivory Soap regimen should be continued 
throughout the test period. 
( 
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N.AME ____________ WEEK # __ 3 __ AP TRT #_1 __ 
Your TREATED side is the axilla. The test 
---
CREAM antiperspirant is to be applied to this a.xilla ONLY. 
-
Your CONTROL side is the a.xilla. NO anti-
perspirant should be applied to this axilla. 
REMINDER: CONTINUE WASHING BOTH AXILLAE WITH IVORY SO.AP AND 
WATER ONLY FOR THE DURATION OF THE EXPERIMENT. 
Application of the test CREAM antiperspirant (ap). 
Note the area outlined by axillary hair under your 
TREATED axilla. Make a rectangle of this area. This is the 
area to which the ap will be applied. Apply the ap provided 
for the assigned day to the clean, dry TREATED axilla ONLY. 
The cream ap should be rubbed on the axilla with the 
glassine wrap. Try to use the entire sample. Allow to dry 
about 1 minute. Return the glassine wrap with any unused 
cream ap in the jar to the investigator the following 
morning. 
The CONTROL axilla should be clean and dry. NO 
antiperspirant is to be applied to this axilla. 
SUNDAY, April 9. Apply the test CREAM ap as directed to the 
treated axilla only. No antiperspirant will be applied to 
the control axilla. The test ap may be worn for the entire 
day. No sweat collection pads will be worn today. 
MONDAY, April 10. Proceed as on SUNDAY. 
TUESDAY, April 11. Apply the test CREAM ap as directed to 
the treated axilla only. Let dry about 1 minute. Snugly 
( 
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tape the sweat collection pads to the designated axilla. 
Wear the pads !or 10 hours. At the end of the 10-hour 
collection period, return the pads to the appropriate 
Ziploc bag. SEAL 'WELL. Return the pads and bags to the 
investigator the following day. 
WEDNESDAY, April 12. Proceed as on TUESDAY. (Sweat 
collection day) 
THURSDAY, April 13. Proceed as on TUESDAY. (Sweat 
collection day) 
FRIDAY, April 14. Recovery period begins. (No sweat 
collected) 
SATURDAY, April 15. Proceed as on FRIDAY. (No anti-
perspirant applied and no sweat collection) 
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WEEK# 4 
SUNDAY, April 16, to FRIDAY, April 21, is a recovery 
period. Continue washing axillae with Ivory Soap and 
water only. NO sweat will be collected. NO anti-
perspirant will be used. 
SATURDAY, April 22. Continue above procedure. Remove 
axillary hair with Surgex as directed on package insert. 
( 
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NAME WEEK# 2 AP TRT # 2 
Your TREATED side is the axilla. The test 
LOTION antiperspirant is to be applied to this axilla only. 
Your CONTROL side is the axil la. NO anti-
perspirant should be applied to this axilla. 
REMINDER: CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND 
WATER ONLY FOR THE DURATION OF THE EXPERIMENT. 
Application of the test LOTION antiperspirant (ap). 
Note the area outlined by axillary hair under your 
TREATED axilla. Make a rectangle of this area. This is the 
area to which the ap will be applied. Apply the ap provided 
for the assigned day to the clean, dry TREATED axilla ONLY. 
Apply the lotion ap with the attached cotton swab. Insert 
the swab into the lotion and apply to the TREATED axilla. 
Try to use the entire sample. Allow the ap to dry about 1 
minute. Break the swab to fit inside the vial and seal 
tightly. Return the vial, containing the swab and any 
remaining lotion, to the investigator the following morning. 
The CONTROL axilla should be clean and dry. NO 
antiperspirant is to be applied to this axilla. 
SUNDAY, April 23. Apply the test LOTION ap as directed to 
the TREATED axilla only. No antiperspirant will be applied 
to the control axilla. The test ap may be worn for the 
entire day. No sweat will be collected today. 
MONDAY, April 24. Proceed as on SUNDAY. 
Tuesday, April 25. Apply the test LOTION ap as directed to 
( 
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the treated axilla only. Let dry about 1 minute. Snugly 
tape the sweat collection pads to the designated axillae. 
Wear the pads for 10 hours. At the end of the 10-hour 
collection period, return the pads to the appropriate 
Ziploc bag. SEAL WELL. Return the pads in the bags to 
the investigator the following day. 
WEDNESDAY, April 26. Proceed as on TUESDAY. (Sweat collection 
day) 
THURSDAY, April 27. Proceed as on Tuesday. (Sweat collection 
day) 
FRIDAY, April 28. Recovery period begins. (No ap application 
and no sweat collection) 
SATURDAY, April 29. Proceed as on FRIDAY. (No ap application 
and no sweat collection) 
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WEEK# 6 
SUNDAY, April 30, to FRIDAY, Hay 5, is a recovery period. 
Continue washing axillae with Ivory Soap and water only. 
NO sweat will be collected. NO antiperspirant will be used. 
SATURDAY, May 6. Continue above procedure. Remove axillary 
hair with Surgex as directed on package insert. 
( 
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N.AME ____________ WEEK # __ 7..._ __ AP TRT # 3 
Your TREATED side is the axilla. The test 
---
CLEAR antiperspirant is to be applied to this axilla only. 
Your CONfROL side is the axilla. NO anti-
perspirant should be applied to this axilla. 
REMINDER: CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND 
WATER ONLY FOR THE DURATION OF THE EXPERIMENT. 
Application of the test CLEAR antiperspirant (ap). 
(The test CLEAR ap is an alcohol-based ap similar to the 
manual pump spray). 
Note the area outlined by axillary hair under your 
TREATED axilla. Make a rectangle 4" by 2" of this area. 
This is the area to which the ap will be applied. Apply 
the ap provided for the assigned day to the clean, dry 
TREATED axilla only. Apply the CLEAR ap with the 
attached cotton swab. Insert the swab into the ap and 
apply to the TREATED axilla. Try to use the entire sample. 
Allow to dry about 1 minute. Break the swab to fit inside 
the vial and seal tightly. Return the vial containing the 
swab and any remaining ap to the investigator the following 
morning. 
The CONTROL axilla should be clean and dry. No 
antiperspir_ant is to be applied to this axilla. 
SUNDAY, May 7. Apply the test CLEAR ap as directed to the 
treated axilla only. No antiperspirant will be applied to 
the control axilla. The test ap ma;y be worn for the entire 
day. No sweat will be collected today. 
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MONDAY, May 8. Proceed as on SUNDAY. (No sweat col-
lection) 
TUESDAY, May 9. Apply the ap as directed to the TREATED 
axilla only. Let dry about 1 minute. Snugly tape the 
sweat collection pads to the designated axillae. Wear the 
pads for 10 hours. At the end of the 10-hour collection 
period, return the pads to the appropriate Ziploc bag. 
SEAL WELL. Return the pads in the bag to the investigator 
the following day. 
-:,JEDNESDAY, May 10. Proceed as on TUESDAY. (Sweat col-
lection day) 
THURSDAY, I1ay 11. Proceed as on TUESDAY. (Sweat col-
lection day) 
FRIDAY, May 12. Recovery period begins. (No sweat 
collection and no antiperspirant applied) 
SATURDAY, May 13. Proceed as on Friday. (No sweat 
collection and no antiperspirant applied) 
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WEEK# _8_ 
SUNDAY, May 14, to FRIDAY, May 19, is a recovery period. 
Continue washing axillae with Ivory Soap and water only. 
NO sweat will be collected. NO antiperspirant will be used. 
SATURDAY, May 20. Continue above procedure. Remove 
axillary hair with Surgex as directed on package insert. 
( 
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NAME WEEK# ~ AP TRT # 4 
Your TREATED side is the axil la. The test 
STICK antiperspirant is to be applied to this axilla only. 
Your CONTROL side is the axil la. NO anti-
perspirant should be applied to this axilla. 
REMINDER: CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND 
WATER ONLY FOR THE DURATION OF THE EXPERIMENT. 
Application of the test STICK antiperspirant (ap). 
Note the area outlined by axillary hair under your 
TREATED axilla. Make a rectangle 4" by 2" of this area. 
This is the area to which the ap will be applied. Apply 
the ap provided for the assigned day to the clean, dry 
TREATED axilla ONLY. The test stick ap may be rubbed in 
with your fingers or by using the glassine wrap. Try to 
use the entire sample. Allow to dry about 1 minute. Return 
the glassine wrap and any unused test stick ap in the jar 
to the investigator the following morning. 
The CONTROL axilla should be clean and dry. NO 
antiperspirant is to be applied to this axilla. 
SUNDAY, May 21. Apply the test stick ap as directed to the 
treated axilla only. No antiperspirant will be applied to 
the control axilla. The test ap may be worn for the entire 
day. No sweat collection pads will be worn today. 
MONDAY, May 22. Proceed as on Sunday. 
TUESDAY, May 23. Apply the test STICK ap as directed to 
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the TREATED a.xilla only. Let dry about 1 minute. Snugly 
tape the sweat collection pads to the designated axillae. 
Wear the pads for 10 hours. At the end of the 10-hour 
collection period, return the pads to the appropriate 
Ziploc bag. SEAL WELL. Return the pads and bag to the 
investigator the following day. 
WEDNESDAY, May 24. Proceed as on TUESDAY. 
THURSDAY, MaY 25. Proceed as on TUESDAY. 
This is the final day of the antiperspirant study. 
Thank you. 
( 
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